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ABSTRACT OF DISSERTATION 
 
EVALUATION OF THE SUSCEPTIBILITY AND HUMORAL IMMUNE RESPONSE 
OF FOALS TO RHODOCOCCUS EQUI INFECTION 
 
While Rhodococcus equi (R. equi) remains the most common cause of subacute or 
chronic granulomatous bronchopneumonia in foals, development of a relevant model to 
study this bacterium has proven difficult. As a result, the reasons for the underlying foal’s 
susceptibility to this disease are not well understood. Furthermore, data regarding the 
immune response of foals to R. equi infection remains controversial. We hypothesized 
that foals are susceptible to R. equi early in life and that this susceptibility decreases with 
age. Also, we hypothesized that specific subclasses of IgG antibodies to the virulence-
associated protein of R. equi, VapA, predict the outcome of exposure. 
The objectives of this study were: (1) to develop an R. equi challenge model that 
resulted in slow progressive disease in some foals as well as spontaneous regression of 
lesions in others, (2) using the developed model, to investigate the age-related 
susceptibility of young foals to R. equi, (3) to describe the humoral immune response of 
foals following experimental challenge and natural infection.  
The use of a low dose of R. equi to challenge neonatal foals resulted in slow, 
progressive disease characterized by pulmonary abscessation and spontaneous regression 
in approximately 50% of the foals. When this low dose was used in 1, 2 or 3-week-old 
foals, a marked decrease in disease susceptibility was observed as the foals aged. The 
immunological responses seen after experimental challenge reflect those observed after 
  
 
natural infection. While there was a significant increase of VapA-specific IgG and IgG 
subclasses over time in both pneumonic and healthy foals, use of VapA-specific IgG(T) 
showed good sensitivity and specificity when used as a diagnostic tool for R. equi 
pneumonia.  
In summary, this study shows that foal susceptibility to R. equi occurs early in life 
and decreases with age.  Whereas all foals developed VapA-specific IgG antibodies post-
exposure, IgG(T) appeared to be predictive of infection. 
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CHAPTER 1 
LITERATURE REVIEW AND RESEARCH OBJECTIVES 
 
Rhodococcus equi (R. equi), is the most devastating cause of subacute or chronic 
bacterial pneumonia in foals less than 6 months of age 
1
. Adult horses are resistant to R. 
equi infection unless they are immunocompromised, but little is known about the reason 
for the unique susceptibility of foals to this infection. This disease has a significant 
financial impact in the equine industry worldwide because of its high incidence, the lack 
of a vaccine and the presence of the bacteria in the soil 
2,3
. This bacterium also affects 
other species such as pigs 
4
, cattle 
5
 goats 
6
 and immunocompromised humans 
7
.  
 
The bacterium 
Rhodococcus equi, a Gram-positive coccobacillus, is an aerobic, facultative 
intracellular pathogen of macrophages. It belongs to the mycolata group of the genus 
Actinobacteria and is characterized by the presence of an outer cell capsule; a mycolic 
acid-containing glycolipid barrier that is thought to protect the cell wall from the immune 
system 
8
. Mycolic acids are linked to the arabinogalactan-peptidoglycan layer of the cell 
wall by covalent links and form a hydrophobic barrier that protects the bacterium 
8
. Some 
components of this lipid barrier may also play a role in pathogenesis. Mutant strains of R. 
equi lacking an enzyme required for elongation of long chain mycolic acids (KasA) have 
decreased capacity to prevent phagolysosome formation 
9
. As a coprophilic soil 
saprophyte, this organism persists and is widely spread in the soil, however, not all 
strains are pathogenic.  Virulent R. equi carries a large circular plasmid (85-90kb), which 
contains a pathogenicity island of around 27 kb with genes encoding 7 virulence-
associated proteins (VapA, VapC to H) 
10
. Only vapA, which encodes the 15-17 kDa 
 2 
 
temperature inducible surface–expressed lipoprotein VapA, is necessary for virulence 11 
as vapA
-
 strains of R. equi cannot replicate in macrophages or cause pneumonia in foals 
12,13
. Moreover, the type of plasmid possessed determines the bacterium’s host specificity.  
Unlike R. equi from horses that possess vapA, isolates from pigs carry vapB plasmid 
(pVAPB) while that from bovines have a different plasmid, pVAPN, negative for pVAPA 
and pVAPB (“N” standing for no-A no-B) 14.  
 
Pathogenesis in foals 
The pathogenesis of R. equi in foals is not well understood but the gastrointestinal 
and respiratory tracts are known routes of infection 
5,15
. Inhalation is considered the major 
route of pulmonary infection 
16
. Once inhaled, R. equi is taken up by the alveolar 
macrophage either by the CR3 (Mac-1) or mannose receptors 
17,18
. Virulent R. equi 
survives inside the phagocytic vacuole due to its ability to alter the acidification process 
19,20
; but the exact mechanism of this process has not been elucidated. Intracellular 
replication of R. equi results in macrophage necrosis, infection of new macrophages and 
pyogranulomatous inflammation 
21
. The incubation period of R. equi after inhalation is 
unknown. Factors such as the amount of virulent bacteria present, the age of the foal and 
the host defense mechanisms likely affect its outcome 
22
.  Oral exposure also occurs early 
in the foal’s life 23 but little is known about its role in development of disease. In one 
study, oral administration of pathogenic R. equi protected foals against experimental 
challenge 
24
. 
 
Clinical signs 
The typical presentation of R. equi in foals is granulomatous bronchopneumonia, 
22,25
 though extrapulmonary disorders occur in more than half of the affected foals 
25,26
. 
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Pneumonia develops insidiously and clinical signs are usually seen between 3-24 weeks 
of life, with the majority of foals showing signs before 16 weeks of age 
22
. The slow 
spread of the infection along with the remarkable ability of foals to compensate for 
progressive loss of pulmonary function complicates early diagnosis. Early disease is 
characterized by fever, lethargy and cough 
27
. Anorexia, tachypnea, increased respiratory 
effort and tachycardia appear as the disease progresses 
27
. Subacute pneumonia, which 
carries poor prognosis, is seen in a small percentage of foals and is characterized by 
respiratory distress and fever 
28
. Extrapulmonary R. equi infections, while reported to be 
present in 50% of the cases 
25,26
 can be difficult to diagnose and many are only found 
during necropsy. Survival was lower among foals with extrapulmonary infections 
26
. 
Granulomatous enterotyphylocolitis, abscessation of mesenteric or other abdominal 
lymph nodes and peritonitis are the most common abdominal presentations 
26
. 
Interestingly, foals with rhodococcal pneumonia rarely show signs of intestinal disease 
25,26
. Synovitis, which presents as effusion of one or more joints, is seen in a third to a 
fourth of the foals with R. equi infection 
26
.  
 
Diagnosis in foals 
Currently, the recommendation for definitive diagnosis of R. equi 
bronchopneumonia is bacteriologic culture or amplification of the vapA gene by PCR 
from a tracheobronchial aspirate obtained from a foal with either clinical signs of lower 
respiratory tract disease, cytological evidence of septic airway inflammation, and/or 
radiographic or ultrasonographic evidence of bronchopneumonia 
29
. However, 
tracheobronchial aspiration is not recommended for foals with severe respiratory distress 
30
. While this approach can be used to confirm clinical cases, identification of early 
 4 
 
infection before clinical signs become apparent remains a challenge 
30
. Thoracic 
ultrasonography has been used as an early screening method for R. equi infection 
31
. 
When used routinely on endemic farms, ultrasound overestimates the true incidence of 
clinically significant disease and results in unnecessary antibiotic use 
32
. While the 
majority of foals have ultrasonographically visible lesions, many of these foals 
spontaneously recover without the aid of treatment and never develop clinical disease 
2,32,33
. These findings, coupled with the fact that macrolide and rifampin resistance has 
increased worldwide, 
34,35
 highlights the need for diagnostic tools capable of detecting 
acute infection. 
 
The lack of an appropriate research model 
Prior to the widespread use of diagnostic imaging, clinical signs were typically 
observed beginning at 2 months of age 
25
.  This timing coincided with the waning of 
maternal antibodies and was presumed to account for disease susceptibility.  However, 
epidemiological evidence indicates that foals are infected shortly after birth 
36-38
, though 
it is unclear how long foals remain susceptible to R. equi. It is also unclear why only a 
few foals develop clinical signs while the majority recovers uneventfully. This lack of 
information is in part due to the absence of a relevant challenge model for this disease in 
foals. A large portion of what is known about R. equi is based on studies performed in 
mouse 
39,40
, although mice are naturally resistant to R. equi infection and effectively clear 
the bacteria after IV or intranasal challenge 
41
. Moreover, the spleen and liver, instead of 
the lungs, are the target organs in mice after systemic infection 
42
. Guinea pigs 
43
 and 
piglets 
44
 have also been used, but neither developed classical pyogranulomatous 
pneumonia after experimental challenge, though the role of virulence-associated plasmid 
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was not fully appreciated when these studies were performed. Even in foals, most studies 
report acute, severe pneumonia characterized by large areas of pulmonary consolidation, 
requiring humane euthanasia 2–3 weeks after intrabronchial or intratracheal challenge 
because of the severity of pneumonia 
45,46
. This accelerated disease progression is likely 
due to the large doses of R. equi used for the challenges 
47
 and does not reflect what is 
seen in the field. An improved model of R. equi infection in foals that results in 
progression of disease similar to that observed after natural exposure is needed to better 
understand the age-related as well as the individual susceptibility to this disease. 
Moreover, such model will allow for evaluation of different treatments and prophylactic 
methods.  
 
The lack of effective prophylactic measures 
Currently, a vaccine to prevent R. equi does not exist and farms with an endemic 
problem attempt to prevent infections by other means.  The method of choice is 
prophylactic IV administration of R. equi-specific hyperimmune plasma (HIP) shortly 
after birth; which may be repeated 4-8 weeks later 
48
.  
Administration of HIP appeared to protect foals from development of disease in 
some field studies 
28,48-50
 and after experimental challenge; 
51,52
 however, other studies 
showed no positive effect 
53-55
. Further, when a control, untreated group was included, 
HIP failed to prevent pneumonia or decrease lesion size or length of treatment in a field 
study 
56
. Results from field studies should be interpreted with caution because of 
limitations such as lack of untreated control foals, 
48,50
 year-to-year variation in disease 
incidence 
48-50
, lack of definitive diagnosis of disease 
49
, variability in age at plasma 
administration 
49,50
, and differences in volume and frequency of plasma administered 
49
.  
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While experimental infection provides a more controlled environment to evaluate 
HIP efficacy, the large challenge doses often used may have overwhelmed the protective 
effects of plasma 
52-54
. Other confounders in these models are the age of the foal at the 
time of administration of HIP and at challenge, 
49,50,53
 the route and dose of infection and 
the extent of exposure 
57
. As epidemiological and experimental data indicates foals are 
most susceptible to infection within the first few weeks of life, 
36,37,58
 early administration 
is critical since HIP appears to be ineffective after infection has occurred 
59
.  
To date, the protective component of HIP remains uncertain 
53
. Plasma provides 
antibodies along with other immune modulators which may enhance the humoral effector 
mechanism against this infection 
60
. Antibodies are thought to be important because of 
their opsonic activity 
15,51,61,62
. Opsonins attach to bacteria and to specific receptors on 
phagocytic cells enhancing phagocytosis 
15
. It is proposed that these antibodies diffuse 
into the airway opsonizing R. equi before it reaches the intracellular compartment 
63
. 
Entry of R. equi into macrophages mediated by macrophage Fc receptors following 
antibody binding leads to enhanced bacterial killing instead of survival as seen after entry 
via the CR3 receptor 
15,17,51,64
. Antibodies have been shown to be beneficial against R. 
equi infection in vitro. Plasma from horses vaccinated with R. equi and from infected 
foals increased the phagocytic activity of their neutrophils 
15,60,61,64,65
 and macrophages as 
well as their oxidative burst activity and TNF-α production 63. Further, opsonizing 
activity of serum to R. equi increased after vaccination with VapA and this opsonizing 
activity was transferred from the vaccinated mares to their foals 
66
. The phagocytic 
activity of foal’s neutrophils was similar to that of adult’s when these cells were 
incubated with adult horse serum. This shows that foal neutrophil function depends on 
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humoral factors, which may change with age, rather than on neutrophil maturation 
60
. In 
this regard, IgG antibodies are considered important opsonins and they account for 80% 
of the total IgG repertoire 
67
. New terminology has been proposed for equine IgG 
subclasses (IgG1 to IgG7) based on the IgG heavy chain constant gene region 
68
. In spite 
of this, the new nomenclature has not been widely embraced likely as a result of the 
unavailability of reagents and the fact that commercially available reagents are still sold 
using the original nomenclature. As a result, original nomenclature will be used 
throughout the rest of this document. A table comparing the original and current 
nomenclature is provided (Appendix, supplementary table 1.). 
In the adult horse, IgG(T), IgGa and IgGb activate complement and strongly 
stimulate a respiratory burst from peripheral blood leucocytes after binding to the Fcγ 
receptor 
69
. These antibodies are produced in a limited fashion in neonatal foals 
70-72
. 
Endogenous production of IgGa and IgG(T) is only evident around 4-5 weeks of age and 
IgGb endogenous synthesis is not significant until foals are 8-12 weeks of age, 
24,70,72,73
  
however, foals have been shown to synthetize all IgG subclasses earlier if the correct 
stimulus is provided 
74
. This relative deficiency of IgG may play a role in the 
development of R. equi pneumonia 
75
 and is reflected in the humoral response of foals to 
vaccination. While vaccine-specific IgGa and IgG(T) significantly increased after 3-day-
old foals were vaccinated twice at 21 day intervals using a cattle product, a significant 
increase in vaccine-specific IgG and IgGb was evident only when 3-month-old foals were 
vaccinated.  Overall, the response of the foals was lower than that seen in adult horses 
76
. 
Since the half-life of immunoglobulins after IV administration ranges from 30-90 days, 
50,67
 and opsonizing activity is retained after thawing, 
60
 HIP is an important source of 
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antibodies until endogenous production of IgG occurs. Moreover, unlike antibodies 
passively acquired by colostrum that depend on humoral response of vaccinated mares, 
quality of colostrum and ability of foal to nurse, HIP administration could provide a 
standardized amount of IgG to the foals. However, significant variability was seen in R. 
equi specific antibodies after HIP administration to foals 
50
.  
Thus, despite its widespread use, convincing evidence to support HIP plasma 
efficacy is lacking. Further, the minimum effective dose to prevent R. equi pneumonia is 
currently unknown. Many factors such as infectious challenge, host susceptibility, age, 
weight, sex and farm management, among others, likely come into play during natural 
infections 
49,58
 and these may have an effect on the HIP dose required for protection. In 
addition, little is known about the quantity or quality of specific anti-R. equi antibodies 
contained in different plasmas. Moreover, there is no standard protocol for HIP 
production. The end plasma product depends on the strain selected for vaccination, the 
dose and adjuvant used, and immunogenic factors of the donor 
58
. Individual horses have 
been shown to respond poorly to vaccination to R. equi 
48
 and significant individual 
variation in the opsonic activity was seen amongst plasma donors 
60
. 
 
The IgG response of foals to R. equi remains unclear 
The possible role that each IgG subclass may play in R. equi infections is poorly 
defined.  This issue is complicated by the contradictory results reported in humoral 
response after infection. Rhodococcus equi specific IgG and fecal bacterial 
concentrations increased over time in foals beginning at 3-5 until 9 weeks of age as a 
result of natural exposure 
77,78
. Pneumonic foals had significantly higher R. equi specific 
IgG and IgGb than exposed adults 
62,77
. Oral and intratracheal inoculation of foals 
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increased R. equi specific IgG, 
57
 and both IgGa and, surprisingly, IgGb, but not IgG(T), 
increased after intrabronchial challenge of neonatal foals 
74
. Adults experimentally 
challenged with R. equi have been shown to have a predominant increase in IgGa, 
62
 
IgGb 
74
or both IgGa and IgGb 
75
. The role of IgG(T) antibodies in R. equi infection is less 
understood.  Pneumonic foals produced IgG(T) antibodies in response to R. equi and this 
response was not seen in adults or exposed healthy foals 
62
. The increase in IgG(T) was 
significantly higher when a larger R. equi inoculum size rather than a small one was used 
to challenge neonatal foals 
47
. While early studies proposed that IgG(T) couldn’t activate 
complement and therefore it was an undesired response to infection, 
62
 IgG(T) has since 
been shown to be the most potent complement activator in horses 
69
. Moreover, VapA-
specific IgG(T) increased after oral immunization with virulent R. equi that successfully 
protected foals 
24
. The role of IgG(T) has been shown to be important in parasitic 
infections. Strongylus vulgaris 
79,80
 and Cyathostome (small strongyle) infections resulted 
in a predominant increase of IgG(T) 
81
. Moreover, the increase seen in IgG(T) correlated 
with the intensity of Anoplocephala perfoliata infection intensity in horses 
82
. IgG(T) was 
also the most efficient antibody to neutralize snake venom 
83
. It is fairly clear from the 
studies described above that further research needs to be conducted in order clarify the 
role of IgG and IgG subclasses in the response of foals to R. equi.  Such knowledge could 
prove useful at the time of diagnosis of this disease.  
 
Serology and diagnosis 
Antibody detection using whole R. equi or crude antigen extracts in ELISAs has 
been previously evaluated as a screening tool to detect early R. equi infection, but this 
method lacked sensitivity due to high background resulting from environmental exposure 
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to this ubiquitous bacterium 
30,62,84
. Methods utilizing antibody detection are also 
confounded by passively transferred antibodies from colostrum and HIP 
85
. Moreover, a 
significant overlap in titers exists between pneumonic and clinically normal foals, which 
is likely due to subclinical disease 
30,86
. In addition, some ELISAs lack the ability to 
differentiate responses to pathogenic and non-pathogenic strains of R. equi.  As a result, 
the specificity of R. equi ELISAs had limited use. Subsequent studies have used a VapA-
specific ELISA to evaluate the antibody response after experimental challenge and 
natural infection 
24,30,75
. While this approach is specific for pathogenic isolates, 
87
 it was 
not useful as a diagnostic tool for rhodococcal pneumonia because clinically healthy foals 
also have antibodies to virulent R. equi 
30
. Moreover, this VapA-specific IgG ELISA has 
never been properly validated. Moreover, little is known about the VapA-specific 
subclasses IgGa, IgGb and IgG(T) for early diagnosis of pneumonia caused by R. equi.   
Thus, despite years of effort, much remains unknown regarding the foal’s 
response to R. equi. As an attempt to advance our knowledge, the following hypotheses 
(H) and specific aims (SA) are proposed: 
 
H1 - Foals are susceptible to R. equi early in life and this susceptibility decreases with 
age. 
(SA) 1-Develop an R. equi challenge model that results in slow progressive 
disease in some foals as well as spontaneous regression of lesions in others. 
(Chapter 2) 
(SA) 2-Use this low dose model to investigate the age-related susceptibility of 
young foals to R. equi. (Chapter 2) 
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H2 - The VapA-specific IgG subclass response can be used to predict the outcome of 
exposure. 
(SA) 1- Validate a VapA-specific ELISA for IgG and its subclasses IgGa, IgGb 
and IgG(T). (Chapter 3) 
(SA) 2- Describe the VapA-specific IgG response of foals following experimental 
challenge and natural infection. (Chapter 4) 
 
 H3 - Variations in HIP can account for the reported disparate efficacies. 
(SA) 1- Describe the variation in VapA-specific IgG and IgG subclasses between 
and within commercial R. equi specific HIP. (Chapter 5) 
(SA) 2- Determine the effect that HIP variation has on the amount of VapA-
specific IgG received by the foals. (Chapter 5) 
 
 
 
 
 
Copyright © Macarena G Sanz 2014 
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CHAPTER 2 
THE EFFECT OF BACTERIAL DOSE AND FOAL AGE AT CHALLENGE ON 
RHODOCOCUS EQUI INFECTION 
 
Veterinary Microbiology, 2013: 167 (3-4), 623-631 
 
Summary 
While Rhodococcus equi remains the most common cause of subacute or chronic 
granulomatous bronchopneumonia in foals, development of a relevant model to study R. 
equi infection has proven difficult. The objective of this study was to identify a challenge 
dose of R. equi that resulted in slow progressive disease, spontaneous regression of lung 
lesions and age-dependent susceptibility. Foals less than one-week of age were 
challenged intratracheally using either 10
6
, 10
5
, 10
4
, 10
3
 or 10
2
 cfu of R. equi.  Two doses 
(10
3
 cfu and 10
6
) were used to challenge 2 and 3-week-old, and 3 and 6-week-old foals, 
respectively. Physical examination, thoracic ultrasound and blood work were performed.  
Foals were euthanized at the end of the study or when clinical signs of pneumonia 
developed. All foals were necropsied and their lung lesions scored.  Foals challenged 
with low concentrations of R. equi developed slow progressive pneumonia and 
approximately 50% of the foals recovered spontaneously. Likewise, macroscopic (> 1 cm 
diameter) pyogranulomatous lesions were only observed when low doses of R. equi were 
used.  Clinical pneumonia was not seen after low dose challenge in the 3-week-old foals 
or in the 6-week-old foals. This study demonstrates that the use of low doses of R. equi to 
challenge neonatal foals provides an improved model for studying this disease.  
Furthermore, susceptibility to R. equi infection was shown to diminish early in the foal’s 
life, as has been reported in the field.  
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Introduction 
Rhodococcus equi (R. equi) remains the most devastating cause of subacute or 
chronic granulomatous bronchopneumonia in foals less than 5 months of age 
88
. Because 
R. equi is ubiquitous and can be endemic in some farms, it has a major financial impact 
on the equine industry 
2
. Nevertheless, little is also known regarding the reason for the 
unique susceptibility of foals to this infection.  Prior to the widespread use of diagnostic 
imaging, clinical signs were typically observed beginning at 2 months of age 
25
. Recent 
evidence indicates that foals are likely infected shortly after birth 
36,37
, though it is unclear 
how long foals remain susceptible to R. equi. This lack of information has been due, in 
part, to the absence of a relevant challenge model for this disease in foals. 
Development of an equine model to study R. equi infection has proven difficult.  
A large portion of what is known about R. equi is based on studies performed in mouse 
models 
39,40
, even though mice are naturally resistant to R. equi infection and effectively 
clear the bacteria after IV or intranasal challenge 
41
. Moreover, the spleen and liver, 
instead of the lungs, are the target organs in mice after systemic infection 
42
. Guinea pigs 
43
 and piglets 
44
 have also been used, but neither develops classical pyogranulomatous 
pneumonia after experimental challenge, though the role of virulence-associated plasmid 
was not fully appreciated when these studies were performed. Even in foals, most studies 
report acute, severe pneumonia characterized by large areas of pulmonary consolidation, 
requiring humane euthanasia 2-3 weeks after challenge because of the severity of 
pneumonia 
46,89
. This accelerated disease progression is likely due to the large doses of R. 
equi used for the challenges 
47
. While R. equi infections in the field may present with a 
wide range of lesions, pyogranulomatous pneumonia usually develops insidiously with 
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slight increases in respiratory rate and mild fever 
1
. If not recognized, the disease may 
become chronic with clinical signs developing over time 
25,90
 or it may completely 
regress without treatment 
2
; however, what determines the outcome remains unknown. 
An improved model of R. equi infection in foals that results in progression of 
disease similar to that observed after natural exposure is needed. Such a model will be 
beneficial for the development of vaccines, evaluation of treatment options, and 
understanding why some foals develop clinical disease while others recover uneventfully. 
The objective of this study was to identify a challenge dose of R. equi which resulted 
either in slow developing pyogranulomatous pneumonia in neonatal foals or lesion 
regression. In addition, the age susceptibility of foals to R. equi was investigated. 
 
Materials and Methods 
 
Study design 
The study was divided into two phases.  Initially, foals less than 1 week of age 
were used to identify a dose of R. equi that would result in clinical disease as well as 
natural regression of lesions without the aid of treatment. Once such a dose was 
identified, it was then used to determine the relative susceptibility of foals at 1 to 3 weeks 
of age. An additional group of 
51
 3 and 6-week-old foals were infected using an R. equi 
strain (103
+
) that has been previously used for experimental challenges 
51,91
 (Appendix, 
Supplementary Figure 2.1). 
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Foals 
Foal of 1-, 2-, 3-, and 6-weeks of age were obtained from the Department of 
Veterinary Science’s equine herd. Foals were enrolled in the studies if they had a normal 
complete physical exam and thoracic ultrasonography along with adequate passive 
transfer of immunoglobulins (>800mg/dl using the SNAP® Foal IgG Test, IDEXX 
laboratories Inc, Westbrook, ME).  Mares and foals were kept on pasture for the duration 
of each study. Each pair (mare and foal) was placed in a stall for a period of 2-3h twice a 
week while samples were collected and clinical exams performed. These studies were 
approved by the University of Kentucky’s Institutional Animal Care and Use Committee 
and Institutional Biosafety Committee.  
 
Challenge (Appendix, Protocol 2.1) 
 
R. equi strain 206 (UKVDL206) was provided by Dr. M. Donahue from the 
University of Kentucky Veterinary Diagnostic Laboratory (UKVDL) and R. equi strain 
103
+
 was provided by Bioniche Animal Health.   The bacteria were stored as a frozen 
stock in 20% glycerol and streaked onto a tryptic soy agar yeast extract (TSAYE) plate 
and incubated at 37 ºC for 48h. To prepare the inoculum, a single typical mucoid, creamy 
colony was selected from the plate, inoculated into tryptic soy yeast broth (TSBYE) and 
incubated at 37 ºC for 48h. Bacterial concentrations were initially estimated based on 
optical density (OD) of the culture media using a spectrophotometer at wavelength 
600nm and confirmed by serial dilution plating. All the isolates were tested for the 
presence of virulence associated plasmid A (VapA) using PCR at the UKVDL. The agar 
plates were held at room temperature for an additional 72h at which point colony 
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morphology was evaluated. Culture media was serially diluted using PBS to a total 
volume of 20 ml to obtain the following total concentration of bacteria: 10
6
, 10
5
, 10
4
, 10
3 
and 10
2
 cfu/ml.  
Prior to challenge, mare and foals were brought into stalls and the foals sedated 
using a combination of IV xylazine (0.5mg/kg) and butorphanol (0.05mg/kg). A flexible 
tube was used to deliver the diluted bacteria (total volume 20ml) to the mid trachea 
(intratracheal instillation). The number of foals inoculated with the dose of each R. equi 
strain and their ages at challenge are shown in Table 2.1 
 
Table 2.1 R. equi dose (cfu), strains used and age of the foal at challenge (weeks).  
Number of foals Dose given (cfu) R equi strain  Age at challenge (weeks) 
3 10
6  
 UKVDL206  1  
4 10
5
  UKVDL206 1  
4 10
4
  UKVDL206 1  
4 10
3
  UKVDL206 1  
3 10
2
  UKVDL206 1  
4 10
3
  UKVDL206 2  
6 10
3
  UKVDL206 3  
3 10
5
 103+ 3 
5 10
5
 103+ 6 
 
Foal evaluation 
After the effects of sedation passed, mares and foals were returned to pasture.  
The foals were observed daily for increased respiratory rate or effort, lethargy and 
anorexia. Complete physical examinations were performed twice a week after challenge 
with UKVDL206 and included heart (HR) and respiratory rates (RR), rectal temperature, 
characterization of nasal discharge (absent, serous, muco-purulent or purulent), foal’s 
attitude (lethargic, anorexic) and close visual examination of the foal’s joints and eyes 
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(aided by a penlight). Respiratory effort was evaluated using a modification of a 
previously described scoring system 
54
 where 0=normal respiratory effort at rest, 1=slight 
increased effort at rest and 3=moderate effort at rest. 
Bilateral thoracic ultrasonography was performed on the foals receiving 
UKVDL206 and was performed prior to challenge and weekly thereafter using a 7.5MHz 
linear probe (CTS-7700V-SIUI, Universal Medical System, Inc, Bedford Hills, NY).  
Each lung was scored, as reported previously 
31
 as a means to monitor disease 
progression in the foals. Briefly, the maximum diameter (mm) of each lesion was 
measured and a score was generated based on the largest lesion found on each foal at a 
given time point. 
Blood was collected before UKVDL206 inoculation and weekly thereafter by 
jugular venipuncture for complete blood cell count (CBC) and fibrinogen with the 
analyses being performed at UKVDL. Serum was batched frozen at -20ºC for serum 
amyloid A (SAA) evaluation using a previously validated immunoturbidimetric assay 
92
 
at the Department of Pathology, University of Miami Miller School of Medicine, Miami, 
FL.  
 
Macroscopic lesions and histopathology 
Foals were euthanized at 6 (UKVDL206) or 8 weeks (103
+
) after challenge or 
sooner if they had evidence of bronchopneumonia upon thoracic ultrasonography and any 
one of the following: fever (temp >102.5F) for 36h; signs of lower respiratory disease for 
12h with any of the following observed; abnormal lung auscultation, crackles, or wheezes 
or signs of rattles auscultated in the trachea; tachypnea: >48 breath/minute resting rate, 
and increased respiratory effort (characterized by abdominal effort and nostril flaring), 
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bilateral mucopurulent or purulent nasal discharge and productive cough. A board 
certified pathologist, blinded to the study design, performed all of the necropsies. 
Macroscopic lesions were scored for the foals challenged with UKVDL206 using a 
system as previously reported 
46
. The percentage of normal and abnormal lung was 
quantitated for each lung lobe. Individual lobe pneumonia scores were added together to 
form a cumulative pneumonia score for each foal that was expressed as a percentage of 
total lung involvement. A lung weight/body weight ratio was calculated 
54,89
. 
Representative lung samples were collected for histopathology from the right and 
left cranial apical regions, right and left middle and dorsal diaphragmatic regions, 
accessory lung lobe, and the tracheobronchial lymph node. Each lung sample was 
microscopically graded as to the degree of pyogranulomatous inflammation (0=no 
inflammation, 1=<5% affected, 2=5-25% affected, 3=25-50% affected, 4=50-75% 
affected, or 5= >75% affected) and distribution of parenchymal necrosis (0=none, 
1=focal, 2=multifocal, 3=focally to multifocally extensive, or 4=diffuse). Lymph node 
samples were histologically graded based on inflammation (0=no inflammation, 1=mild, 
2=moderate or 3=severe) in the capsule and subcapsular trabecular and medullary 
sinuses.  Lymph node necrosis determination was based on the distribution of the 
necrosis (0=no necrosis, 1=focal, 2=multifocal to coalescing or 3=diffuse). A 
histopathologic pneumonia score was generated for each foal by adding the inflammation 
and necrosis scores for all lung sections together. Similarly, a cumulative lymph node 
score was generated by adding both, the inflammation and necrosis scores.       
Four distinct patterns of pneumonia (types A, B, C, and D) were recognized and 
classified (Figure 2.1). Type A lesions consisted of large well-demarcated granulomas. 
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Microscopically, type A lesions were composed of a central locally extensive necrotic 
core of cell debris, acidophilic proteinaceous material, and low numbers of neutrophils 
and macrophages. The necrotic core was surrounded by an inner inflammatory layer of 
low to moderate numbers of epithelioid macrophages, neutrophils, and lesser numbers of 
multinucleated giant cells. Macrophages and multinucleated giant cells contained 
occasional phagocytized bacteria. The inner inflammatory layer was surrounded by an 
outer fibrovascular tissue capsule that was infiltrated with low to moderate numbers of 
lymphocytes, plasma cells, and macrophages. Type B lesions consisted of poorly-
demarcated fibrotic nodular regions that replaced and disrupted the normal pulmonary 
parenchyma. Nodular regions were microscopically composed of arborizing bands and 
sheets of collagen-rich fibrous connective tissue that was infiltrated with low numbers of 
epithelioid macrophages, lymphocytes, and plasma cells and occasional multinucleated 
giant cells. Entrapped individual bronchioles and alveolar spaces were multifocally 
distributed throughout the fibrotic regions. Entrapped airways contained low numbers of 
epithelioid macrophages and multinucleated giant cells, occasional lymphocytes and 
neutrophils, and small amounts of acidophilic proteinaceous material and cell debris; 
associated alveolar spaces were frequently lined by hypertrophied and hyperplastic type 2 
pneumocytes. Type C lesions consisted of well-demarcated red, firm, consolidated 
regions. Histologically, a majority of alveoli, bronchioles, and bronchi within type C 
lesions contained low to moderate numbers of epithelioid macrophages, neutrophils, and 
occasional multinucleated giant cells intermixed with small amounts of fibrin, acidophilic 
proteinaceous material, and cell debris. Phagocytized bacteria were frequently evident in 
macrophages and multinucleated giant cells. Within the inflammatory foci were 
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occasional poorly demarcated regions of alveolar septal necrosis. The adjacent pleura and 
interstitium were mildly fibrotic and infiltrated with minimal to low numbers of 
lymphocytes, plasma cells, and neutrophils.  Type D lesions grossly consisted of well-
demarcated, small, multifocal to coalescing pyogranulomas.  Histopathologically, these 
lesions had a central necrotic center composed of cell debris intermixed with low to 
moderate numbers of neutrophils, epithelioid macrophages, and occasional 
multinucleated giant cells.  Macrophages and multinucleated giant cells often contained 
phagocytized bacteria.  The necrotic core was frequently surrounded by a thin to 
moderate fibrous connective tissue capsule that was infiltrated with low numbers of 
lymphocytes and plasma cells.   
 
 
Figure 2.1 Macroscopic pulmonary lesions.  Left: Type A (well-demarcated granulomas, 
arrow) and C (poorly demarcated red, firm, consolidated foci, arrow head). Middle: Type 
B lesion (poorly-demarcated tan, firm, arborizing region) Inset: higher magnification of 
the boxed region displaying the lesion. Right: Type D lesion (small, multifocal to 
coalescing pyogranulomas). The bar represents 2cm.  
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Bacteriology 
One-cm
3
 tissue samples were obtained for bacterial culture. Samples were 
routinely collected from the cranial apical, middle and dorsal diaphragmatic lung lobes 
and from the tracheobronchial lymph node (Supplementary figure 2.2). Abdominal lymph 
nodes were also collected for the 1, 2 and 3-week old foals that received the 10
3
 cfu 
(UKVDL206) dose.  Small sections of tissue were placed into sterile 1.5ml Eppendorf 
tubes and homogenized for 3 minutes at 30Hz using a Retsch MM301 Ball Mill (Newton, 
PA), as previously described 
93
. Afterwards, serial dilutions of the supernatants were 
performed and aliquots were plated onto TSAYE plates and incubated at 37 ºC for 48h. 
The number of colonies/g of tissue was then calculated (Supplementary figure 2.3). 
Colonies were observed for typical R. equi characteristics (large, mucoid colonies that 
developed a red pigment over a 72h period). Gram stain, PCR identification of the 
organism and the presence of VapA were confirmed on selected colonies.  
 
Statistical analysis 
 
Survival times by age and dose groups were compared using Kaplan-Meier 
estimates of survival probability, with foals surviving until the end of the study treated as 
censored.  ANOVA models were used to analyze the relationship between age/dose 
groups and necropsy, other histopathology scores and bacteriology data; p-values 
reported refer to the global (or “omnibus”) test unless otherwise stated.   To estimate 
changes in physical examination and blood work measurements over time, rates of 
change per week were calculated for each foal by least squares.  ANOVA models were 
then fit to these slopes to determine associations between age/dose groups and changes in 
these measurements over time. Correlations between physical examination/blood work 
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measurements and necropsy scores were also calculated and their significance tested 
using linear regression. 
 
Results 
For the UKVDL206 challenge, the median age (range) at challenge of the 1-week 
old foals (n=18) used for the dose selection portion of the study was 3 days (2-7) and it 
was not different between dosage groups (p= 0.52). The median age (range) of the 2-
week-old foals (n=4) was 12 days (10-14).  The median age (range) of the 3-week-old 
foals (n= 6) was 19 days (17-21).   The median age (range) for those 3 (n=3) and 6-week-
old (n=5) foals challenged using R. equi 103+ was 22 (18-24) and 47 (39-54) days, 
respectively.  All bacterial isolates used to challenge the foals were VapA positive (by 
PCR) and developed typical colonies on TSAYE plates.  
 
Thoracic ultrasonography 
Ultrasound was only available for the foals challenged using UKVDL206. 
Ultrasound images were collected for 2 of 3 foals from the 10
6 
group, 3 of 4 foals from 
the 10
5
 group and for all the remaining foals. Pulmonary abnormalities were observed in 
all foals after challenge. Ultrasonographic lesions consistent with R. equi pneumonia 
94
 
featuring well-defined hypoechoic nodules (Figure 2.2) were observed in one week old 
foals receiving the lower doses whereas large areas of consolidated lung were present in 
those foals receiving the higher doses.  Lesion size decreased over time in 2 of 4 and 2 of 
3 the one-week-old foals that received 10
3
 and 10
2
 cfu, respectively (Figure 2.2).  Lesion 
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size also decreased over time in 2 of 4 foals challenged at 2 weeks of age and in 4 of 6 
foals challenged at 3 weeks of age.   
 
Figure 2.2 Thoracic ultrasonography of a newborn foal challenged with a low dose of R. 
equi (10
2
 cfu) obtained at 4 (left), 5 (middle) and 6 (right) weeks of age. A well-defined 
circular hypoechoic area is observed in the periphery of the left cranial ventral region of 
the lung, consistent with pulmonary abscessation caused by R. equi infection. The lesion 
cross sections measured 26.1mm, 17.8mm and 9.3mm at 4,5 and 6 weeks of age 
respectively. The ultrasounds were performed using a 7.5 MHz linear probe. 
 
Blood work (Tables 2.2 and 2.3) 
 
Pack cell volume, hemoglobin and red blood cell counts were significantly 
different over time between doses (p<0.01), decreasing when high doses of bacteria were 
inoculated (10
4
, 10
5
 and 10
6 
cfu).  Changes over time between doses were not different 
for mean cell volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), WBC, neutrophil or monocyte counts. Lymphocyte 
counts were different between doses over time (p=0.02), increasing in foals that received 
fewer bacteria. A significant correlation was observed between WBC (p=0.04, R
2
=0.42), 
fibrinogen (p=0.02, R
2
=0.28) and SAA (p=0.014, R
2
=0.32) concentration at the time of 
euthanasia and necropsy scores on one-week-old foals.   
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Clinically significant changes over time were not observed for any of the blood 
work parameters evaluated on foals challenged at 2 or 3 weeks of age. Though a 
significant correlation was observed between SAA concentration at the time of 
euthanasia and necropsy scores (p<0.002, R
2
=0.64). 
 
Physical examination (Tables 2.4 and 2.5) 
 
There was no significant change in HR or the presence of lethargy between doses 
over time. Significant changes over time were observed in RR (p=0.001, R
2
=0.76), 
respiratory effort (p=0.02, R
2
=0.57) and temperature (p=0.003, R
2
= 0.69) as well as 
worsened lung sounds (p=0.02, R
2
=0.55) when high doses of bacteria were given. R. equi 
associated extrapulmonary lesions, including both ocular and joint abnormalities, were 
not observed in any of the foals. Foals assigned higher necropsy scores had significantly 
higher respiratory rates (p=0.006, R
2
=0.38) and temperatures (p<0.0001, R
2
=0.75) at the 
time of euthanasia than those with lower necropsy scores.  
Temperature increased (p=0.052, R
2
=0.41) over time in foals challenged at one 
and two weeks of age. Fever was not present in any of the foals challenged at 3-weeks of 
age. There were no other significant changes observed over time between ages for any of 
the physical exam parameters (Table 1.5).  Foals assigned higher necropsy scores had 
significantly higher temperature (p<0.001, R
2
=0.69) at the time of euthanasia than those 
with lower necropsy scores.  
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Table 2.2 Blood work for each challenge dose of UKVDL206 by time point.*  
Challenge 
dose (cfu) 
Time 
point 
PCV  
(%) 
RBC 
(x106cells
/ul) 
HGB 
(g/dl) 
MCV 
(g/dl) MCH (fL) 
MCHC 
(g/dl) 
WBC 
(x103cells
/ul) 
NT 
(x103cells
/ul) 
LT 
(x103cel
ls/ul) 
Mono 
(x103cells
/ul) 
Fibrinogen 
(mg/dl) 
SAA 
(mg/L) 
  
            
  
106 0 39.9 ± 4.7 9.6 ± 1.3 12.8 ± 1.2 41.2 ± 0.7 13.3 ± 0.6 32.2 ± 0.8 6.8 ± 1.5 4.4 1.1 0.1 600 ± 0 36± 7 
  1 33.4 ± 2.7 8.4 ± 1 10.7 ± 1 39.8 ± 4.6 12.7 ± 1.0 32 ± 1.2 10.4 ± 0.6 8.5 ± 0.7 1.6 ± 0.4 0.2 ± 0.1 433 ± 200 36 ± 6 
  2 31.2 ± 2.8 8.2 ± 0.2 9.8 ± 0.8 38.0 ± 4.3 11.9 ± 1.3 31.4 ± 0.1 4.34 ± 0.3 2.6 ± 0.5 1.3 ± 0.3 0.3 ± 0.1 850 ± 353 2289 ± 524 
  
            
  
105 0 41.8 ± 6 10.4 ± 0.7 13.4 ± 1.5 39.9 ± 3.5 12.9 ± 0.7 32.3 ± 1.1 7.5 ± 1.8 4.4 ± 3.3 0.9 ± 0.8 0.2 ± 0.2 400 ± 141 80 ± 40 
  1 37.1 ± 4.8 9.1 ± 0.7 11.7 ± 1.4 40.3 ± 2.1 12.8 ± 0.6 31.7 ± 0.7 11.3 ± 2.8 9.7 ± 2.3 1.3 ± 0.9 0.1 ± 0.1 375 ± 125 41 ± 11 
  2 32.6 ± 3.5 8.3 ± 0.4 10.3 ± 1.3 39.1 ± 2.4 12.3 ± 1.0 31.6 ± 0.7 8.5 ± 1.7 6.8 ± 1.7 1.2 ± 0.7 0.3 ± 0.3 525 ± 95 539 ± 484 
  
            
  
104 0 37.7 ± 4.7 9.0 ± 1 12.2 ± 1.4 41.7 ± 1.6 13.6 ± 0.8 32.5 ± 1.1 8.1 ± 4.0 6.5 ± 3.5 1.3 ± 0.4 0.1 ± 0.1 375 ± 189 48 ± 10 
  1 38.6 ± 2.9 9.32 ± 0.8 12.4 ± 0.7 41.8 ± 0.9 13.5 ± 0.6 32.3 ± 0.8 8.7 ± 1.2 6.6 ± 0.7 1.8 ± 1.2 0.2 ± 0.1 400 ± 100 40 ± 12 
  2 35 ± 4.6 8.8 ±1 11.4 ± 1.6 39.5 ± 0.7 12.8 ± 0.5 32.5 ± 0.7 11.4 ± 4.4 9.9 ± 4.4 1.4 ± 0.5 0.1 ± 0.1 475 ± 50 96 ± 117 
  
            
  
103 0 36.8 ± 5.3 8.8 ± 1 11.9 ± 1.6 41.5 ± 2.4 13.4 ± 0.5 32.3 ± 0.9 8.4 ± 1.0 6.7 ± 0.7 1.4 ± 0.9 0.3 ± 0.2 300 ± 163 42 ± 3 
  1 34.6 ± 3.1 8.4 ± 0.9 11.1 ± 1.1 40.9 ± 2.1 13.1 ± 0.8 32.1 ± 0.5 8.6 ± 2.0 6.8 ± 1.8 1.4 ± 0.5 0.2 ± 0.2 300 ± 81 34 ± 3 
  2 38.5 ± 6.4 9.5 ± 1.6 12.3 ± 2.8 40.2 ± 0.3 12.7 ± 0.8 31.8 ± 2.1 10.8 ± 0.4 8.1 ± 0.8 2.2 ± 0.6 0.5 ± 0.2 350 ± 70 264 ± 331 
  3 33.7 ± 3.1 8.8 ± 1.4 10.7 ± 1.1 38.4 ± 2.5 12.2 ± 0.6 31.7 ± 0.4 9.5 ± 0.8 7.0 ± 0.6 1.9 ± 0.2 0.5 ± 0 650 ± 70 248 ± 293 
  4 36.4 ± 1.4 9.6 ± 0.5 11.8 ± 0.1 37.6 ± 1.5 12.2 ± 0.6 32.4 ± 1.1 17.6 ± 5.5 14.4 ± 5.0 2.3 ± 0.7 0.9 ± 0.3 666 ± 115 308 ± 474 
  5 36.2 ± 1.8 9.9 ± 0.1 11.9 ± 0.1 36.4 ± 2.2 12.0 ± 0.2 33.0 ± 1.5 16.2 ± 0.8 13.0 ± 1.0 2.4 ± 0.3 0.5 ± 0.2 400 ± 0 30 ± 8 
  6 37.3 ± 1.3 10.2 ± 0.8 11.9 ± 0.4 36.4 ± 1.4 11.6 ± 0.5 32.0 ± 0.1 11.7 ± 1.0 8.9 ± 2.2 2.5 ± 1.0 0.1 ± 0 400 ± 141 32 ± 2 
  
            
  
102 0 36.6 8.8 11.6 41.8 13.3 31.7 7.5 6.3 1.1 0.2 400 37 ± 14 
  1 37.6 ± 3.2 8.6 ± 0.8 12.0 ± 0.8 43.4 ± 0.2 13.8 ± 0.4 31.9 ± 1.0 8.9 ± 0.6 7.1 ± 1.4 1.4 ± 0.7 0.3 ± 0.2 250 ± 200 31 ± 30 
  2 37.9 ± 3.2 9.1 ± 0.8 12.1 ± 0.8 41.5 ± 0.2 13.3 ± 0.4 32.1 ± 1.0 7.9 ± 0.6 5.6 ± 1.4 2.0 ± 0.7 0.2 ± 0.2 400 ± 200 51 ± 30 
  3 38.5 ± 2.3 9.6 ± 0.6 12.4 ± 0.5 39.9 ± 0.6 12.9 ± 0.3 32.3 ± 1.1 8.4 ± 2.5 5.8 ± 2.8 2.2 ± 0.4 0.2 ± 0.2 400 ± 100 32 ± 5 
  4 35.2 ± 1.6 9.0 ± 0.4 11.3 ± 0.3 39.0 ± 0.2 12.5 ± 0.2 32.1 ± 0.5 9.1 ± 3.5 6.3 ± 2.7 2.4 ± 0.5 0.3 ± 0.3 500 ± 100 72 ± 81 
  5 37.5 ± 2.5 9.7 ± 0.6 12.1 ± 0.6 38.5 ± 0.1 12.4 ± 0.2 32.3 ± 0.6 9.9 ± 0.6 6.9 ± 0.9 2.8 ± 0.8 0.2 ± 0.1 433 ± 57 27 ± 2 
  6 38.8 ± 3.2 10.1 ± 0.8 12.9 ± 1.2 38.2 ± 0.4 12.6 ± 0.3 33.1 ± 0.5 14.1 ± 1.6 11.2 ± 1.4 2.1 ± 0.4 0.6 ± 0.2 300 ± 100 154 ± 212 
  7 39.1 ± 0.8 10.5 ± 0.1 12.8 ± 0.1 37.3 ± 0.4 12.2 ± 0.1 32.8 ± 0.5 12 ± 1.1 8.4 ± 1.1 3.2 ± 0.1 0.2 ± 0 500 ± 141 38 ± 5 
*Results are expressed as average ± standard deviation (SD).  SD is not shown when data for <2 foals was available. TP0 represents 
the sample collected before challenge (2-7 days of age); thereafter, samples were collected on weekly basis. NT (neutrophils), LT 
(lymphocytes), Mono (monocytes), SAA (Serum Amyloid A).  
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Table 2.3 Blood work for foals challenged using 10
3
 cfu of UKVDL206 at 1, 2 or 3 weeks of age.*  
Age at 
infection 
Time 
point 
PCV  
(%) 
RBC 
(x106cells/
ul) 
HGB 
(g/dl) 
MCV 
(g/dl) 
MCH 
(fL) 
MCHC 
(g/dl) 
WBC 
(x103cells/
ul) 
NT 
(x103cell
s/ul) 
LT 
(x103cell
s/ul) 
Mono 
(x103cells/
ul) 
Fibrinogen 
(mg/dl) 
SAA 
(mg/L) 
  
            
  
1 week  0 36.8 ± 5.3 11.9 ± 1.6 41.5 ± 2.4 13.4 ± 0.5 32.3 ± 0.9 8.4 ± 1.0 8.8 ±1.0 6.7 ± 0.7 1.4 ± 0.9 0.3 ± 0.2 300 ± 163 43 ± 3 
  1 34.6 ± 3.1 11.1 ± 1.1 40.9 ± 2.1 13.1 ± 0.8 32.1 ± 0.5 8.6 ± 2.0 8.4 ± 0.9 6.8 ± 1.8 1.4 ± 0.5 0.2 ± 0.2 300 ± 81 34 ± 3 
  2 38.5 ± 6.4 12.3 ± 2.8 40.2 ± 0.3 12.7 ± 0.8 31.8 ± 2.1 10.8 ± 0.4 9.5 ± 1.6 8.1 ± 0.8 2.2 ± 0.6 0.5 ± 0.2 350 ± 70 264 ± 331 
  3 33.7 ± 3.1 10.7 ± 1.1 38.4 ± 2.5 12.2 ± 0.6 31.7 ± 0.4 9.5 ± 0.8 8.8 ± 1.4 7.0 ± 0.6 1.9 ± 0.2 0.5 ± 0 650 ± 70 248 ± 293 
  4 36.4 ± 1.4 11.8 ± 0.1 37.6 ± 1.5 12.2 ± 0.6 32.4 ± 1.1 17.6 ± 5.5 9.6 ± 0.5 
14.4 ± 
5.0 2.3 ± 0.7 0.9 ± 0.3 666 ± 115 308 ± 474 
  5 36.2 ± 1.8 11.9 ± 0.1 36.4 ± 2.2 12.0 ± 0.2 33.0 ± 1.5 16.2 ± 0.8 9.9 ± 0.1 
13.0 ± 
1.0 2.4 ± 0.3 0.5 ± 0.2 400 ± 0 30 ± 8 
  6 37.3 ± 1.3 11.9 ± 0.4 36.4 ± 1.4 11.6 ± 0.5 32.0 ± 0.1 11.7 ± 1.0 10.2 ± 0.8 8.9 ± 2.2 2.5 ± 1.0 0.1 ± 0 400 ± 141 32 ± 2 
  
            
  
2 weeks  -1 39.0 ± 5.0 9.8 ± 1.2 12.7 ± 1.8 39.9 ± 0.3 13.0 ± 0.3 32.5 ± 0.6 9.7 ±1.6 8.5 ± 1.9 0.9 ± 0.2 0.2 ± 0 300 ± 0 27 ± 17 
  0 35.7 ± 2.3 8.7 ± 0.8 11.5 ± 0.7 41.3 ± 0.9 13.3 ± 0.3 32.3 ± 0.1 10.8 ± 4.3 9.8 ± 4.8 0.9 ± 0.5 0.1 ± 0 400 ± 0 26 ± 9 
  1 33.0 ± 3.1 8.2 ± 1.1 10.8 ± 1.0 40.5 ± 1.5 13.2 ± 0.5 32.6 ± 0.2 7.7 ± 1.6 6.5 ± 1.1 1.0 ± 0.5 0.1 ± 0.1 375 ± 50 89 ± 97 
  2 35.0 ± 3.0 8.9 ± 1.1 11.5 ± 1.2 39.5 ± 1.5 12.8 ± 0.3 32.4 ± 0.7 9.2 ± 2.6 7.1 ± 1.6 1.5 ± 0.6 0.4 ± 0.7 500 ± 230 125 ± 167 
  3 33.5 ± 1.5 8.6 ± 0.3 10.7 ± 0.6 39.0 ± 0.8 12.4 ± 0.6 31.8 ± 1.1 9.7 ± 4.7 7.8 ± 3.9 1.4 ± 0.3 0.4 ± 0.5 475 ± 95 13 ± 7 
  4 34.9 ± 3.9 9.1 ± 1.0 11.3 ± 1.1 38.3 ±0.9 12.4 ± 0.4 32.4 ± 0.6 10.5 ± 4.0 8.8 ± 3.5 1.4 ± 0.6 0.3 ± 0.1 450 ± 100 52 ± 63 
  5 35.6 ± 3.5 9.4 ± 0.9 11.4 ± 1.1 37.8 ± 0.5 12.0 ± 0.2 31.8 ± 0.1 10.2 ± 3.3 7.9 ± 3.0 1.9 ± 0.5 0.4 ± 0.2 450 ± 57 12 ± 3 
  
            
  
3 weeks -2 36.2 ± 3.1 8.7 ± 0.7 12.1 ± 1.0 41.6 ± 1.7 13.8 ± 0.3 33.2 ± 0.7 8.2 ± 0.7 6.6 ± 0.9 1.3 ± 1.0 0.2 ± 0.2 240 ± 114 45 ± 52 
  -1 35.6 ± 3 8.7 ± 0.8 11.2 ± 1.0 40.3 ± 2.5 13.0 ±1.0 32.0 ± 1.1 9.7 ± 2.9 8.1 ± 3.2 1.4 ± 0.5 0.2 ± 0.1 380 ± 83 178 ± 309 
  0 36.6 ± 2.4 9.1 ± 0.5 11.5 ± 0.7 40.2 ± 2.5 12.6 ± 0.6 31.5 ± 0.6 9.1 ± 1.8 6.9 ± 1.7 1.9 ± 0.5 0.3 ± 0.2 416 ± 40 24 ± 5 
  1 35.5 ± 1.3 9.1 ± 0.2 11.4 ± 0.4 39.0 ± 1.9 12.5 ± 0.6 32.0 ± 1.2 10.9 ± 3.4 8.6 ± 3.2 2.1 ± 0.4 0.2 ± 0.1 466 ± 81 24 ± 4 
  2 35.9 ± 3.4 9.4 ± 0.9 11.5 ± 1.1 38.4 ± 1.5 12.4 ± 0.6 32.2 ± 0.9 10.9 ± 2.7 8.4 ± 2.3 2.1 ± 0.6 0.4 ± 0.4 400 ± 167 19 ± 5 
  3 36.7 ± 3.2 9.8 ± 0.8 11.8 ± 1.2 37.7 ± 1.8 12.2 ± 0.7 32.2 ± 0.7 12.5 ± 1.8 9.1 ± 1.3 3.2 ± 0.8 0.2 ± 0.1 450 ± 105 17 ± 6 
  4 40.8 ± 9.9 10.9 ± 2.4 13.1 ± 3.3 37.7 ± 1.5 12.1 ± 0.4 32.1 ± 1.0 11.2 ± 3.3 8.0 ± 3.2 2.7 ± 1.1 0.4 ± 0.3 433 ± 51 20 ± 9 
  5 38.1 ± 3.0 10.2 ± 0.7 12.3 ± 0.9 37.3 ± 1.4 12.1 ± 0.4 32.4 ± 0.7 11.8 ± 2.5 7.3 ± 2.1 4.0 ± 0.7 0.6 ± 0.4 400 ± 154 16 ± 5 
* The results are presented as average ± standard deviation (SD). TP0 represents the sample collected before challenge; thereafter, 
samples were collected on weekly basis. TP-1 and TP-2 represent samples collected one and two weeks prior to challenge, 
respectively. NT (neutrophils), LT (lymphocytes), Mono (monocytes), SAA (Serum Amyloid A).
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Table 2.4 Physical exam results for foals challenged using different doses of 
UKVDL206 at one week of age.* 
 
*Exams were performed twice weekly and the results are presented as average ± 
standard deviation for each week. TP0 represents the exams performed before 
challenge. 
 
 
  
Challenge dose 
(cfu) 
Time 
point 
Heart rate 
(beats/min) 
Respiratory rate 
(breaths/min) 
Temperature 
(°C) 
  
   
  
10
6
 0 83 ± 9 35 ± 7 38.7 ± 0.7 
 
1 87 ± 25 49 ± 16 39.3 ± 0.8 
 
2 83 ± 9 35 ± 7 38.6 ± 0.7 
     10
5
 0 93 ± 24 41 ± 13 38.5 ± 0.2 
 
1 84 ± 15 47 ± 13 38.8 ± 0.4 
 
2 76 ± 13 61 ± 18 39.5 ± 0.5 
     10
4
 0 94 ± 14 45 ± 12 38.4 ± 0.3 
 
1 88 ± 18 47 ± 12 38.7 ± 0.3 
 
2 73 ± 14 50 ± 16 39.2 ± 0.7 
     10
3
 0 104± 33 54 ± 14 38.6 ± 0.2 
 
1 90 ± 16 48 ± 14 38.6 ± 0.2 
 
2 76 ± 27 42 ± 6 38.6 ± 0.2 
 
3 59 ± 28 45 ± 9 38.9 ± 0.5 
 
4 83 ± 31 42 ± 4 38.5 ± 0.1 
 
5 84 ± 12 36 ± 11 38.6 ± 0.2 
     10
2
 0 102± 20 55 ± 6 38.4 ± 0.5 
 
1 78 ± 21 47 ± 15 38.7 ± 0.1 
 
2 79 ± 22 39 ± 3 38.3 ± 0.5 
 
3 63 ± 13 39 ± 6 38.5 ± 0.6 
 
4 66 ± 14 37 ± 3 38.5 ± 0.3 
 
5 60 ± 12 40 ± 7 38.6 ± 0.1 
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Table 2.5 Physical exam results for foals challenged using 10
3
 cfu of UKVDL206 at 1, 
2 or 3 weeks of age.*  
Age at 
challenge Time point 
Heart rate  
(beats/min) 
Respiratory rate  
(breaths/min) 
Temperature 
(°C) 
  
   
  
1 week 0 104 ± 33 54 ± 14 38.6 ± 0.2 
  1 90 ± 16 48 ± 14 38.6 ± 0.2 
  2 76 ± 27 42 ± 6 38.6 ± 0.2 
  3 59 ± 28 45 ± 9 38.9 ± 0.5 
  4 83 ± 31 42 ± 4 38.5 ± 0.1 
  5 84 ± 12 36 ± 11 38.6 ± 0.2 
  
   
  
2 Weeks -1 80 ± 19 53 ± 11 38.5 ± 0.2 
  0 75 ± 9 42 ± 7 38.6 ± 0.4 
  1 61 ± 12 34 ± 5 38.5 ± 0.3 
  2 61 ± 22 35 ± 9 38.5 ± 0.3 
  3 55 ± 12 34 ± 7 38.3 ± 0.5 
  4 55 ± 11 30 ± 14 38.2 ± 0.6 
  5 65 ± 10 28 ± 15 38.2 ± 0.4 
  
   
  
3 weeks -2 88 ± 13 37 ± 10 38.6 ± 0.5 
  -1 82 ± 19 49 ± 11 38.5 ± 0.1 
  0 79 ± 21 46 ± 10 38.3 ± 0.3 
  1 66 ± 12 34 ± 9 38.5 ± 0.2 
  2 66 ± 11 35 ± 12 38.5 ± 0.2 
  3 65 ± 9 33 ± 9 38.5 ± 0.2 
  4 56 ± 6 33 ± 6 38.3 ± 0.2 
  5 55 ± 10 32 ± 7 38.2 ± 0.2 
  6 60 ± 7 28 ± 9 38.2 ± 0.2 
* Exams were performed twice a week and the results are presented as average ± 
standard deviation of each week. TP0 represents the exams performed before challenge.  
TP-1 and TP-2 represent samples collected one and two weeks prior to challenge, 
respectively. 
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Survival (Figure 2.3) 
 
There was a significant effect of dose on survival (p<0.0001). All foals that 
received high doses (10
6
, 10
5
, 10
4
 cfu) of UKVDL206 and half of the foals that 
received 10
3
 cfu were euthanized before the end of the study because they developed 
clinical sings of pneumonia (increased respiratory rate and effort, respiratory distress, 
fever, anorexia, lethargy) thus meeting the euthanasia criteria. The remaining foals 
were euthanized at the end of the study. The average (SD) time to euthanasia was 13 
(±1) days post-inoculation for the 10
6
 group, 15 (±0) days for 10
5
 group, 17 (±2) days 
for 10
4
 group, 33 (±11)  days for 10
3 
group and 43 (±0) days (end of the study) for the 
10
2
 group.   
Half of the foals challenged using UKVDL206 at 1 and 2 weeks of age were 
euthanized before the end of the study because they met the criteria for euthanasia.  
None of the foals challenged at 3 weeks of age developed clinical signs.  
All of the 3-week-old foals challenged using 10
5
 cfu of 103+ met the criteria for 
euthanasia prior to the end of the study.  By contrast, all the foals challenged at 6 weeks 
of age remained clinically normal for the study period. There was a significant effect of 
age on survival (p=0.008). 
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Figure 2.3 Top left: Survival probability of one-week-old foals challenged using 
different doses of R. equi (UKVDL206). There was a significant effect of dose on 
survival (P<0.0001). Top right: Survival probability of foals challenged using 10
3
 R. 
equi (UKVDL206) at 1, 2 or 3 weeks of age. Bottom: Survival probability of foals 
challenged using 10
5
 R. equi (strain 103+) at 3 or 6 weeks of age. There was a 
significant effect of age on survival (P<0.008). The “x axis shows the days post 
challenge and the “y” axis represents the survival probability of foals after challenge. 
 
Necropsy and histopathology  
Macroscopic necropsy (p<0.01), histologic pneumonia (p=0.02) and fibrosis 
(p=0.04) scores, and lung weight to body weight ratio (p=0.04) were significantly 
higher when a dose of ≥104cfu UKVDL206 was administered. Lymph node 
inflammation scores were not different between doses (p=0.16) (Figure 2.4). 
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Figure 2.4 A significant association was found between the dose of bacteria used to 
challenge and the gross necropsy scores (top left, p<0.01), pneumonia (top right, 
p=0.02) and fibrosis histological scores (bottom left, p=0.01) as well as body weight to 
lung weight ratio (bottom right, p<0.01). The box plots represent the median, upper and 
lower quartiles, while the dots represent the individual data points.  Error bars represent 
95% confidence intervals. 
 
The macroscopic pneumonia scores and the type of lesions observed varied with 
the different doses of UKVDL206 (Figure 2.5). Macroscopic pneumonic lesions were 
identified in all of the foals inoculated with high doses of bacteria (10
6
, 10
5
 and 10
4
 
cfu). Both, type C and D lesions were evident in these foals in all ventral lung segments 
sampled but discrete type D lesions were also occasionally present in all lung segments.   
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Macroscopic pneumonic lesions were identified in 3 of 4 foals inoculated using a dose 
of 10
3
 cfu.  Types A, B and C lesions were observed in these foals. Type A lesions 
measured up to 2.5 cm in diameter and were frequently surrounded by type C lesions.  
All lesion types were distributed throughout all segments of the lung. Macroscopic 
pneumonic lesions were identified in 2 of 3 foals inoculated using a dose of 10
2
 cfu 
UKVDL206. Type A and B lesions were observed in the mid-ventral areas of the lung. 
Type A lesions measured 1.5 - 3 cm in diameter.  
 
 
Figure 2.5 Lungs collected at necropsy of foals challenged using 10
6
, 10
5
,10
4
 (left top 
to right) and 10
3 
and 10
2 
cfu (bottom left to right), respectively. Cranioventral lung 
consolidation (type C lesion) and small nodules (type D lesion) are noted on large areas 
of the lungs after high doses of R. equi were administered (gray arrows). Focalized 
abscesses (solid arrow) with minimal consolidation are observed when low (10
3 
and 10
2 
cfu) doses were used.  The bar represents 2cm. 
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The percentage of lung affected (p=0.04) and the degree of tracheobronchial 
lymph node inflammation (p<0.01) were significantly lower in older than younger foals 
and the lung weight to body weight ratio was significantly (p=0.003) higher for 
younger foals. Histological pneumonia (p=0.37) and fibrosis scores (p=0.30) were not 
significantly different between different the age groups (Figure 2.6). 
 
 
Figure 2.6 Top left: Older foals had a significantly (p=0.04) lower percentage of lung 
affected and tracheobronchial (TB) lymph node inflammation (p<0.01, top right) than 
did younger foals. The lung weight to body weight ratio was significantly (p=0.003) 
lower in young than old foals (bottom left). 
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Lesions A, B and C were observed in foals challenged on weeks 1 and 2 of age 
and the lesions were commonly present and distributed thorough the lungs. Type C 
lesions were frequently located adjacent to type A lesions. Lesions type A and B were 
most commonly identified in foals challenged at 3 weeks of age with a single well-
demarcated type C lesion present in one of the 3-week- old foals. 
 
Bacteriology  
When high doses (10
6
 and 10
5
 cfu) of UKVDL206 were inoculated, large 
numbers of bacteria per gram of tissue were isolated from all tissue sample locations. 
As the dose decreased, significantly lower numbers of bacteria were enumerated per 
gram of lung (p=0.027) and tracheobronchial lymph node (p=0.021) tissue and bacterial 
isolation was localized to specific lung regions.(Table 2.6) The number of bacteria per 
gram of lung tissue was significantly (p=0.022 for UKVDL206 and p=0.036 for 103+) 
lower in older foals after challenge with either strain of R. equi (Table 2.7). The number 
of bacteria per gram of tracheobronchial lymph node tissue was significantly (p=0.008) 
lower on older foals after challenge with UKVDL206. 
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Table 2.6 R. equi isolation from standardized lung samples by challenge dose.* 
Dose (cfu) Lung TB LN 
10
6
 3.2x10
7
 NA 
  6.0x10
6
 1.4x10
7
 
  2.6x10
6
 7.2x10
5
 
   10
5
 1.1x10
7
 6.5x10
4
 
  1.4x10
6
 3.5x10
6
 
  
 
  
10
4
 1.1x10
7
 7.0x10
5
 
  2.3x10
7
 3.5x10
3
 
  3.0x10
5
 1.0x10
4
 
  5.1x10
4
 1.9x10
4
 
  
 
  
10
3
 8.0x10
3
 574 
  14 55 
  111 30 
  1.5x10
5
 4.3x10
3
 
  
 
  
10
2
 445 97 
  24 271 
  0 274 
*Average of 6 lung samples per foal collected at necropsy from one-week-old foals 
challenged using different doses of UKVDL206. The results show total cfu/g of tissue 
isolated from both lungs (combined) and tracheobronchial (TB LN) lymph node. NA 
indicates that sample was not available for analysis. 
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Table 2.7 R. equi isolation from standardized lung samples collected at necropsy from 
foals challenged at either 1, 2 or 3 weeks of age.*  
Age at challenge Lung TB LN Abd LN 
  
  
  
1 week 8003 574 NA 
  14 55 0 
  111 30 37 
  157602 4324 81 
  
  
  
2 weeks 1551 64 40 
  28176 22 1 
  0 0 0 
  3 54 2 
  
  
  
3 weeks 0 0 0 
  4 16 0 
  5 2 0 
  0 0 0 
  0 0 0 
  0 0 0 
*Average of 6 lung samples per foal challenged with 10
3
 cfu of UKDVL. The results 
show total cfu/g of tissue isolated from both lungs (combined) and the tracheobronchial 
(TB LN) and abdominal (Abd LN) lymph nodes. NA indicates that samples were not 
available. 
 
Discussion 
Consistent with other reports 
13,46,95
 neonatal foals given large doses ( ≥104 cfu) 
of R. equi had to be euthanized because they developed severe acute pneumonia where 
consolidation was observed in extensive areas of the lungs.   
This acute pneumonia differs from the pyogranulomatous pneumonia that 
develops insidiously and is frequently observed on endemic farms 
1
.  Clinical 
abnormalities were observed in all high dose challenged neonatal foals as they 
developed acute pneumonia. As such, there was a correlation between increased 
respiratory rate and effort, increased temperature and severity of the pneumonia. Serum 
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fibrinogen was markedly elevated in these foals and the increases were correlated with 
the amount of damage to the lung.  While elevations of plasma fibrinogen were seen in 
foals with pneumonia caused by R. equi, this also occurred in other bacterial 
pneumonias and is thus not unique or specific for R. equi 
96
.  Serum amyloid A (SAA), 
an acute phase protein and a sensitive marker of inflammation 
97
, was significantly 
increased over time after challenge and this increase was correlated with the degree of 
pneumonia. Others have found that SAA is not helpful for early diagnosis of R. equi 
pneumonia 
98
 but useful in monitoring disease progression 
99
, as in this study.   Thus, 
the clinical changes seen in these foals were consistent with an acute bacterial 
pneumonia, though not necessarily that caused by R. equi. 
At necropsy, a high lung to body weight ratio was observed in the high dose 
foals and in younger foals as pneumonic lungs have been shown to be heavier than 
those of normal foals 
54,89
.  
Both type C and D lesions were present in young foals challenged with high 
doses of R. equi (UKVDL206 or 103
+
) whereas field infections usually develop type A 
and B lesions 
100
. Not surprisingly, R. equi was isolated from all of the lung samples 
and tracheobronchial lymph nodes when high doses of R. equi were used.  By contrast, 
intratracheal administration of 10
3
 cfu of R. equi resulted in half of the foals developing 
clinical pneumonia that met our criteria for euthanasia.  The remaining foals, as well as 
all of the foals receiving 10
2
 cfu, remained clinically normal with evidence of 
pulmonary lesion regression upon ultrasound evaluation.  This spontaneous lesion 
regression often occurs in foals naturally infected with R. equi 
2,32
.  The mechanism 
responsible for this regression remains unknown.  While lymphocyte counts increased 
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over time in foals that were challenged with the low dose of bacteria, this is likely an 
effect of age as lymphocyte counts increase over time in healthy foals 
101
.  Overall, 
WBC was a poor predictor of disease severity, as has been reported for clinical cases of 
rhodococcosis 
2,96
.  Similarly, serum fibrinogen and SAA were only elevated prior to 
necropsy in the clinically affected foals and there was no change in the clinically 
normal foals.  These results are consistent with the clinical findings seen in field cases 
of rhodococcal pneumonia in foals. 
At necropsy, the low dose challenged foals presented with one or multiple 
coalescing pyogranulomas as can be seen following natural infection 
5,25
 with R. equi 
localizing to specific areas of the lung. Furthermore, arborizing fibrotic foci, type B 
lesions, in the foals challenged using low R. equi doses were also seen.  The presence of 
these characteristic lesions supports the ultrasonographic observations of lesion 
regression, consistent with that observed on endemic farms where some foals develop 
clinical disease while others remain subclinical 
16
 or even completely regress without 
treatment 
2
.  
Clinical pneumonia did not occur during the observation period in 3-week-old 
foals inoculated with 10
3
 cfu (UKVDL206). Moreover, the percentage of affected lung 
on these foals and the number of bacteria isolated from multiple sites was significantly 
lower than that observed in 1 and 2 week-old foals challenged using the same dose of 
R. equi.  While all of the 3-week-old foals challenged using 10
5
 cfu (103
+
) developed 
clinical signs of pneumonia, none of the 6-week-old foals did. In addition, the older 
foals had significantly lower numbers of bacteria isolated from their lungs. Together, 
our results are consistent with field studies indicating young foals are more susceptible 
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to infection 
36,37
.  The demonstration of spontaneous regression in these foals is 
consistent with prior work showing age-related susceptibility to experimental challenge 
15
 and with recent field studies 
2,32
. 
One of the limitations of this study was the small number of foals used.  Thus, 
some of the parameters that were evaluated as predictors of disease may not have been 
significant because of the lack of power in our analyses.  Also, since all foals were 
euthanized at the end of the study, it was not possible to determine whether the 
subclinical foals would have become clinical or resolved their lesions.  
In conclusion, the use of high doses of R. equi to challenge foals resulted in 
acute, severe pneumonia characterized by large areas of pulmonary consolidation and 
severe pneumonia.  Challenge with low doses of R. equi resulted in the development of 
insidious disease characterized by pyogranulomatous pneumonia similar to that 
observed in clinical cases of R. equi infections. Spontaneous regression of lung lesions 
was also observed, as has also been seen on endemic farms.   While evidence from field 
studies indicates that foals are infected with R. equi shortly after birth, it remained 
unclear how long foals remained susceptible. We have demonstrated that foals 3 weeks 
and older showed decreased susceptibility to infection.  
 
 
 
 
Copyright © Macarena G Sanz 2014 
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CHAPTER 3 
VALIDATION AND EVALUATION OF VapA-SPECIFIC IgG AND IgG 
SUBCLASSES ELISAs TO IDENTIFY FOALS WITH RHODOCOCCUS EQUI 
PNEUMONIA 
 
Equine Veterinary Journal, in press (2014) 
 
Summary 
Rhodococcus equi is a common cause of foal pneumonia; however its diagnosis 
remains a challenge for equine veterinarians. While the VapA-specific IgG ELISA has 
low sensitivity and specificity for detecting pneumonic foals, little is known about 
VapA-specific IgG subclasses. The objective of this study was to evaluate the 
performance of VapA-specific ELISA for IgG and its subclasses IgGa, IgGb and 
IgG(T) in the early diagnosis of pneumonia caused by R. equi. The VapA-specific 
ELISA was validated using serum samples from exposed (n=125) and non-exposed 
(n=10) adult horses from Iceland. The diagnostic performance of VapA-specific IgG 
and its subclasses was evaluated using banked serum samples from pneumonic (n=21) 
and healthy (n=80) foals. Sera from exposed and non-exposed adult horses and from 
experimentally challenged and naturally infected foals were used for ELISA validation. 
 Necropsy and tissue culture records of the last 24 years from the Institute for 
Experimental Pathology at the University of Iceland in Keldur, Iceland laboratory were 
evaluated to confirm the absence of R. equi cases in Iceland. To evaluate each IgG 
assay, a cut-off value was selected based on ROC curve analysis and used to calculate 
sensitivity and specificity. The intra and inter-assay coefficient of variation were 
calculated for each ELISA. Using sera from Iceland, where R. equi infection has not 
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been reported, the VapA-specific IgG ELISA differentiated exposed from non-exposed 
horses. When used to identify infected foals, VapA-specific IgG, IgGa and IgGb had no 
diagnostic value. In contrast IgG(T) had high sensitivity and specificity. In conclusion, 
horses from Iceland are not exposed to VapA
+
 R. equi and can serve as negative 
controls. VapA-specific IgG subclasses, with the exception of IgG(T), are poor 
predictors of disease. Further investigation on the use of IgG(T) as a diagnostic tool 
under field conditions is needed.  
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Introduction 
Rhodococcus equi (R. equi), a Gram-positive facultative intracellular pathogen, 
is the most devastating cause of pneumonia in foals between 3 weeks and 5 months of 
age 
1
. Currently, the recommendation for definitive diagnosis of R. equi 
bronchopneumonia is bacteriologic culture or amplification of the vapA gene by PCR 
from a tracheobronchial aspirate obtained from a foal with either clinical signs of lower 
respiratory tract disease, cytological evidence of septic airway inflammation, and/or 
radiographic or ultrasonographic evidence of bronchopneumonia 
29
. While this 
approach can be used to confirm clinical cases, identification of early infections before 
clinical signs become apparent remains a challenge. Although thoracic ultrasonography 
has been used as an early screening method for R. equi infection; 
31
 recent studies have 
shown that the majority of foals with ultrasonographic lesions will resolve their 
infection without treatment 
2,32
. Thus, ultrasonographic screening overestimates the true 
incidence of clinically significant disease and can result in unnecessary antibiotic use. 
These findings, coupled with the fact that macrolide and rifampin resistance has 
increased worldwide, 
34,35
 highlights the need for a diagnostic tool capable of detecting 
acute infection. 
Antibody detection using whole bacterium or crude antigen extraction in 
ELISAs has been previously evaluated as a screening tool to detect early R. equi 
infection, but this method lacked sensitivity due to antibody production that results 
from environmental exposure 
30,62,84
. Methods utilizing antibody detection are also 
confounded by passively transferred antibodies from colostrum and hyperimmune 
plasma 
85
. In addition, some ELISAs lack the ability to differentiate between 
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pathogenic and non-pathogenic strains of R. equi.  Together, these issues limited the 
specificity of this approach. 
More recent studies have used a VapA-specific ELISA to evaluate the response 
after experimental challenge or natural infection 
24,30,75,84,102
. The advantage of this 
approach is that it is specific for pathogenic isolates containing the virulence-associated 
plasmid which encodes the VapA protein 
12
. While this VapA-specific ELISA is widely 
used, little is known about the performance of this test.  Therefore, the objective of this 
study was to evaluate the VapA-specific ELISA for IgG and its subclasses IgGa, IgGb 
and IgG(T) for the early diagnosis of pneumonia caused by R. equi. 
 
Materials and methods 
 
VapA purification (Appendix, Protocol 3.1) 
Recombinant VapA protein was produced and purified using an Escherichia 
coli strain that contained a VapA plasmid fused to glutathione-S-transferase, as 
previously described 
51
. The purity of the protein was assessed by sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE).
b 
  
 
Source of reference control sera 
Positive and negative control sera were included in each plate. A mare 
previously vaccinated with killed VapA
+
 R. equi was used as the positive control.  
Negative control sera included fetal equine serum (FES) and serum obtained from a 4-
month-old foal with negative necropsy and lung tissue culture for R. equi. The foal 
belonged to the University of Kentucky Equine research herd where R. equi pneumonia 
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does not routinely occur. In addition, commercially available R. equi specific 
hyperimmune plasmas were used to construct standard curves. The standard curves for 
VapA-specific IgG, IgGa and IgGb were constructed using one product (ReSolution
c
) 
while a different one (EquiplasR
d
 ) was used for VapA-specific IgG(T) because it had 
higher concentration of this IgG subclass. All reference sera were divided into 100µl 
aliquots and stored at -20°C until used.  
 
VapA-specific enzyme-linked immunosorbent assay development (Appendix, Protocol 
3.2) 
The ELISA for VapA-specific IgG was based on previously described methods 
62,78
 and slightly modified. The VapA, serum and conjugates were titrated to achieve the 
optimal concentration using checkerboard titrations (data not shown). Briefly, 96-well 
microplates
e 
were coated with recombinant VapA (0.5ug/well) in carbonate buffer
f 
and 
allowed to incubate overnight at 4°C. Afterwards, a mixture of blocking buffer 
(polyvinyl alcohol [Mowiol 6–98]6 1% [w/v] in distilled water) and phosphate-buffered 
(PBS, to a final concentration of 1:1[v/v]) was added. Serum was diluted (1:100) in 
PBS with 0.05% Tween-202 (PBST) and added to duplicate wells and incubated at 
37ºC for 1h. Either goat anti-horse IgG conjugated with horseradish peroxidase (HRP)
g
 
(1:10,000) or murine anti-IgGa (1:2, CVS48) anti-IgGb (1:5  CVS39) or anti-IgG(T) 
(1:2, CVS40) (all hybridomas provided by P. Lunn, North Carolina State University) 
were then added and incubated for 1h at 37ºC.  The subclass plates were washed and 
goat anti-mouse IgG-HRP
h 
(1:2000) was added for an additional hour at 37ºC. Plates 
were washed between each step with PBST using an ELISA plate washer (MW 
96/384)
i. The substrate (3,3’,5,5’-tetra-methylbenzidine, peroxidase substratej) was then 
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added for five minutes. The reaction was stopped using stop solution
j
.  Absorbance was 
read at 450nm using an ELISA plate reader
b
. Results from the test sera were converted 
to ELISA units (EU) utilizing a logarithmic trend line from the standard curve 
generated for IgG and each subclass 
103
. A coefficient of determination (r
2) of ≥ 0.90 for 
the standard curve was required for the results to be considered valid 
104
. 
 
Validation methods for VapA-specific enzyme-linked immunosorbent assay  
To estimate assay repeatability, a total of 12 samples ranging from high (n=4), 
intermediate (n=4), low (n=3) and negative (n=1) were selected to evaluate intra-assay 
variation. Three replicates of each sample were run on the same plate and the procedure 
was repeated 10 times. The inter-assay variation was evaluated by repeating 4 samples 
(2 high, 1 intermediate, 1 negative) on 5 different days. The coefficient of variation (% 
CV) from the replicates of each sample and between plates were then calculated 
105
.  
Samples (Table 3.1) used to measure the sensitivity included sera from 
experimentally infected foals (n= 21) from a previous study 
106
, mares vaccinated with 
killed virulent R. equi (n=7), and a 3-month-old foal with rhodococcal osteomyelitis of 
the phalanx. A group of foals diagnosed in the field with rhodococcal pneumonia based 
on age, clinical signs and ultrasound of the thorax was also included, though definitive 
diagnosis was not available (n=12).  
 To evaluate the specificity of the test, serum from a variety of horses exposed 
to R. equi was used (Table 3.1): healthy newborn (<3d-old) foals post suckling as 
previously described 
107
, foals ranging from 2-4m of age euthanized for other reasons 
that lacked pulmonary pathology and had negative lung tissue for R. equi, a control 
yearling that had not exhibited clinical signs nor had ultrasonographic lesions of R. equi 
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as a foal, 3 adults and one 4-month-old foal with non- R. equi respiratory infections 
(Streptococcus zooepidemicus pneumonia isolated from lung tissue or influenza 
complicated with secondary bacterial infection other than R. equi diagnosed after 
culture of transtracheal wash aspirate). Sera from broodmares in the Lexington, KY 
area was also included.  An additional group of sera collected from Icelandic horses 
located in Iceland (n=10), where R. equi pneumonia has not been reported, were used to 
evaluate VapA-specific IgG performance. To support the statement that R. equi 
pneumonia does not occur in Iceland, records from all equine necropsies and cultures of 
equine origin from the last 24 years performed at the Institute for Experimental 
Pathology at the University of Iceland in Keldur, Iceland were examined.  Moreover, to 
rule out the possibility that antibodies were low in these horses due to some breed-
related inability of Icelandic horses to respond to R. equi, serum was collected from 
Icelandic horses imported to the US (n=16) and from Icelandic horses born in the US 
(n=12). 
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Table 3.1 Number of horses included in the study and the median (range) ELISA Units 
(EU) for each of the VapA-specific IgG subclasses evaluated. NT refers to samples that 
were not tested. 
 
Statistical analysis 
The overall diagnostic performance of the ELISA for VapA-specific IgG 
subclasses was assessed by the use of receiver-operating characteristic (ROC) curves 
30
 
constructed using positive and negative foals. The cut-off value for each VapA-specific 
ELISA was calculated using the results of the ROC curve distribution, which was based 
on a combination of good sensitivity with high specificity 
105
. The area under the curve 
(AUC) for each VapA-specific IgG subclass was determined using computer software 
(SigmaPlot
k
). The AUC is a summary statistic of overall diagnostic performance. The 
closer the AUC is to a value of 1, the higher the diagnostic value of the test 
30
.  
The ability of VapA-specific IgG ELISA to differentiate between exposed and 
non-exposed adult horses was evaluated using ROC curve analysis. In this case, a group 
 
Sample 
  
n 
  
VapA IgG 
Median (range) 
EU 
VapA IgGa 
Median (range) 
EU 
VapA IgGb 
Median (range) 
EU 
VapA IgG(T) 
Median (range) 
EU 
 
N
eg
at
iv
e
 
Broodmares 97 2.3 (0.3-22.3) 1.9 (1.1-11.1) 2.5 (1.4-12.1) 2 (1.7-6.1) 
Newborn foals post suckle 80 1.9 (0.9-10.3) 3.8 (1.2-27.9) 3.6 (2.2-47.4) 2.1 (1.9-2.7) 
4m old foal no R. equi 1 2.6 2.1 1.9 2 
Yearling no R. equi 1 1.2 1.3 1.1 2.6 
Adults respiratory disease 
(no R. equi) 3 2.5 (2.5-3.4) 2.8 (2.4-3.4) 3.3 (2.6-3.5) 2.6 (2.6-5) 
Ic
el
an
di
c Iceland 10 1 (1-1.3) NT NT NT 
Imported  to  the US 16 2 (1.2-10.6) NT NT NT 
Born in the US 12 2 (1.2-3) NT NT NT 
P
os
iti
ve
 
Mares vaccinated once 4 74.4 (58-84) 47.2 (40-149) 72.9 (28-89) 2.9 (2.9-3) 
Mares vaccinated twice 3 338.3 (276-355) 91.5 (56.6-106.5) 291.6 (129-331) 1.9  (1.9-2.2) 
Foals 8w post R. equi 
challenge 
21 
2 (1-8) 4 (2-162) 3 (2-12) 3 (2-5238) 
3m old foal R. equi 
osteomyelitis 1 1.5 4.7 1.2 5737 
Presumptive R. equi 
pneumonia 12 2.5 (0.4-6.6) 7 (3-24.1) 1.9 (0.8-11.3) 10.4 (1.1-2439) 
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of broodmares and adult horses from Rhodococcus endemic farms in Lexington, KY, 
were considered true positive (exposed) and a group of horses from Iceland were 
considered true negatives (non-exposed). 
Distribution of each data set was assessed using the Shapiro-Wilk normality 
test. When variables were not Gaussian distributed non –parametric tests were used. To 
compare ELISA units between populations, Kruskal-Wallis one-way ANOVA on ranks 
and Mann-Whitney U tests were used. Pairwise multiple comparisons were performed 
using the Dunn’s method. The analysis was performed 2-tailed and significance was set 
at p<0.05. 
 
Results 
The intra-assay coefficient of variation (CV) and 95% confidence interval (CI)  
are shown in table 3.2. 
 
Table 3.2 Intra and inter-assay coefficient of variations (CV) and 95% confidence 
interval for each VapA-specific IgG ELISA 
Immunoglobulin Intra-assay CV (95% CI) Inter-assay CV (95% CI) 
IgG 8.1 (9.5, 6.7) 10.6 (15, 6.1) 
IgGa 8.1 (9.6, 6.5) 19 (27, 10.9) 
IgGb 10.3 (12.2, 8.4) 13.4 (21, 5.8) 
IgG(T) 11.8 (15.9, 7.8) 7.7 (10.1, 5.3) 
 
 As shown by the ROC curves (Figure 3.1), VapA IgG(T) significantly 
(p=0.0001) outperformed the rest of the subclasses in identifying infected foals.  
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Figure 3.1 ROC curve analysis of VapA-specific IgG subclasses. Foals with culture-
confirmed R. equi infection (n=21) were compared to clinically healthy 1-week-old 
foals (n=80).  The AUC (A) are shown in the graph. VapA-specific IgG(T) significantly 
(p=0.0001) outperformed the rest of the IgG subclasses. 
 
Based on the evaluation of the ROC curves for each VapA-specific IgG 
subclass, the optimal cut-off for each ELISA was selected (Table 3.2) and the 
corresponding sensitivity and specificity calculated. Based on these results, the 
predictive value of a positive or negative test at various disease prevalence’s was 
calculated only for IgG(T) (Figure 3.2). 
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Table 3.3 Performance of each VapA-specific IgG subclass for foals with 
experimentally induced R. equi pneumonia (n=21) and clinically healthy control foals 
(n=80). 
 
Area under ROC 
curve (95% CI) EU Cut-off Sensitivity Specificity 
IgG 0.59 (0.45-0.73) 2.2 45 68 
IgGa 0.58 (0.43-0.73) 3.8 19 56 
IgGb 0.07 (0.28-0.57) 4.4 19 77 
IgG(T) 0.99 (0.97-1.004) 2.7 90 96 
 
 
Figure 3.2 Predictive value of a positive or negative test for VapA-specific IgG(T) at 
various disease prevalences using a cutoff  ELISA units ≥ 2.7.  Foals with culture-
confirmed R. equi infection (n=21) were compared to clinically healthy 1-week-old 
foals (n=80).   
 
The test performance for each VapA-specific IgG subclass was evaluated using 
a group of 2-5 month-old foals that were presumptively diagnosed with R. equi 
pneumonia in the field (Table 3.4). 
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Table 3.4 Performance of each VapA-specific IgG subclass for a group of naturally 
infected foals with presumptive diagnosis of R. equi pneumonia (n=14) and clinically 
healthy control foals (n=80). 
 
Area under ROC curve 
(95% CI) EU Cut-off Sensitivity (%) Specificity (%) 
IgG 0.52 (0.31-0.73) 2.2 43 74 
IgGa 0.73 (0.57-0.89) 3.8 85 56 
IgGb 0.13 (-0.03-0.3) 4.4 0 75 
IgG(T) 0.78 (0.56-1.009) 2.7 79 100 
 
Mares that were vaccinated using a killed R. equi bacterin had significantly 
higher VapA-specific IgG (p<0.001), IgGa (p<0.001) and IgGb (p<0.001) than mares 
that were not vaccinated (Figure 3.3). VapA-specific IgG(T) was not significantly 
different between the two groups (p=0.16).  Further, foals born from these vaccinated 
mares had significantly higher VapA-specific IgG (p<0.001), IgGa (p<0.001) and IgGb 
(p<0.001) than foals from unvaccinated mares; however levels of VapA-specific 
IgG(T) were not different (p=0.07). 
 
 
Figure 3.3 (Left) VapA-specific antibody response in vaccinated and unvaccinated 
mares. (Right) VapA-specific antibody response in foals born from vaccinated and 
unvaccinated mares.  Asterisk (*) indicates statistical significance (p<0.001). 
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Evaluation of the records from the Institute for Experimental Pathology at the 
University of Iceland in Keldur, Iceland revealed that all 643 necropsies performed, 
including 48 foals, were negative for macroscopic lesions consistent with R. equi. 
Moreover, there were no positive isolates obtained from cultures from equine 
origin.(Table 3.5) Sera from Icelandic horses that live in Iceland had significantly 
(p<0.001) lower VapA-specific IgG than Icelandic horses imported to the US, Icelandic 
horses and broodmares born in the US.(Figure 3.4) There was no significant difference 
(p>0.05) between the VapA-specific IgG of Icelandic horses living in the US (imported 
or born) and a broodmare population (p>0.05). VapA-specific IgG subclasses were not 
evaluated further as Icelandic horses from Iceland had almost undetectable levels of 
VapA-specific IgG. Based on these findings, Icelandic horses from Iceland are not 
exposed to VapA
+
 R. equi and can be used as true negatives for differentiating exposed 
from non-exposed adult animals. When this was done, VapA-specific IgG had high 
sensitivity and specificity (Figure 3.5 and Table 3.6). 
Table 3.5 Summary of the records from the Experimental Pathology at the University 
of Iceland of which all were negative for R. equi. 
Period 
Equine 
necropsies 
Foal 
necropsies 
Bacteriological samples 
(equine) 
1990-2000 361 31 433 
2001-2010 220 17 676 
2011 to date 62 0 89 
Total 643 48 1198 
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Figure 3.4 VapA-specific IgG measured in Icelandic horses in Iceland (n=10), imported 
from Iceland (n=16) and those born in the US (n=12).  Also included for comparison is 
a group of Thoroughbred mares (n=97). Populations with different letters are different 
from each other at p<0.001  
 
Table 3.6 Performance of VapA-specific IgG for exposed (n= 125) and non-exposed 
(n=10) adult horses.   
 
Area under ROC curve (95% CI) EU Cut-off Sensitivity Specificity 
IgG 0.97 (0.94-1.002) 2.2 85 100 
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Figure 3.5 ROC curve analysis of VapA-specific IgG.  Non-exposed horses (n=10) 
were compared to exposed horses (broodmares n=97, Icelandic horses imported to the 
US n=16 and born in the US n=12). The AUC (A) from this analysis is shown. 
 
Discussion  
Although serology has been evaluated as a screening tool to detect early R. equi 
infection, sensitivity has been reported to be low due to the antibody production that 
results from exposure to environmental R. equi or from passive transfer 
62,84,108
. Further, 
early methods failed to differentiate between pathogenic and non-pathogenic R. equi.  
Here we have evaluated a VapA-specific ELISA for IgG and 3 different subclasses: 
IgGa, IgGb and IgG(T). The VapA-specific ELISA has been widely used; however 
62,66,75
 information regarding its performance is incomplete. In our study, adequate 
intra- and inter-assay CVs were obtained using this ELISA. Analytical specificity was 
not tested as VapA is unique to R. equi having no known homologues in other bacteria 
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109
. In addition, VapA
+ 
has been identified in horse isolates but was absent in isolates 
from bovine or pigs, which suggests host-driven exclusion of specific plasmid types 
14
. 
A variety of samples have been previously used as negative controls for ELISA 
specificity calculations. Adult horses have the disadvantage of possessing circulating 
antibodies to VapA, likely in response to environmental exposure 
85
. Sera from 
newborn foals have also been used 
24
; however passive transfer of maternal antibodies 
to R. equi by colostrum occurs 
66,85
 and can result in high values. When these samples 
were used as negative controls in our study, VapA-specific IgG and IgGb performed 
poorly. VapA-specific IgGa had low sensitivity and specificity when young foals (<2m) 
were evaluated after experimental challenge (data not shown), but the test performance 
improved when older foals (>2m) were included. This finding was expected, as 
endogenous production of IgGa requires time 
70
. In contrast, IgG(T) had high 
sensitivity and specificity for rhodococcal pneumonia in both young and old foals. This 
IgG subclass has been reported to increase after experimental challenge 
24,75
 and after 
natural infection, 
62
 though this is the first time that its appearance was evaluated as a 
marker for disease. In contrast to the significant increase seen in VapA-specific IgGa 
and IgGb after vaccination with killed R. equi, IgG(T) did not increase; as a result foals 
born from these vaccinated mares had low IgG(T) levels. Immunoglobulin G subclasses 
have been reassigned based on the IgG heavy chain constant gene region 
110
. In spite of 
this, the new nomenclature has not been widely embraced; hence the original 
nomenclature was used in this study. Additional work will be needed to similarly assess 
all IgG subclasses, once these reagents become widely available.  
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While VapA
+
 R. equi is considered an ubiquitous bacterium with world-wide 
distribution 
111
 our results indicate it is likely not present in Iceland. The facts that 
clinical cases of R. equi have not been reported in Iceland, characteristic lesions have 
not been identified in necropsy, and the organism has not been cultured from tissues in 
the past 24 years support this assumption.  Since macroscopic lesions of rhodococcosis 
are characteristic 
25
 and R. equi is easily isolated from tissues 
112
, it is unlikely that the 
disease has been undetected.  As shown by the antibody response in both imported and 
Icelandic horses born in the US, this breed is capable of producing VapA-specific IgG. 
To the authors’ knowledge, this provides the first serologic evidence that a group of 
adult horses, living under natural conditions are unexposed to pathogenic R. equi. Using 
sera from this true negative group of horses to establish a cut-off for the VapA-specific 
ELISA, most US horses were positive, even when the overall level of antibodies was 
quite low. A low level of VapA-specific IgG in adult horses has previously been 
reported 
66
 and is likely a consequence of exposure to pathogenic R. equi in their 
environment.   
In conclusion, we confirmed that VapA-specific IgG subclasses, with the 
exception of IgG(T), are poor predictors of disease due to the presence of antibodies 
caused by environmental exposure. By contrast, VapA-specific IgG(T) had good 
sensitivity and specificity in young foals. A limitation of this study is the lack of 
definitive diagnosis of naturally infected foals; hence, further investigation of this test 
under field conditions is needed.   
 
Copyright © Macarena G Sanz 2014  
  
 
57 
 
CHAPTER 4 
ADMINISTRATION OF COMMERCIAL RHODOCOCCUS EQUI SPECIFIC 
HYPERIMMUNE PLASMA RESULTS IN VARIABLE AMOUNTS OF IgG 
AGAINST PATHOGENIC BACTERIA IN FOAL’S SERUM  
 
 Veterinary Record, in press (2014) 
 
Summary 
Rhodococcus equi is the most common cause of pneumonia in young foals. A 
vaccine is not available and the use of R. equi specific hyperimmune plasma (HIP) is 
common. Despite its widespread use, the efficacy of HIP in preventing disease remains 
controversial. The objectives of this study were (1) to evaluate the virulence associate 
protein A (VapA) specific IgG and IgG subclasses in commercially available R. equi 
HIP and (2) to evaluate serum VapA-specific IgG and IgG subclasses in foals following 
administration of commercial R. equi HIP.  
Three different lots from 4 commercial R. equi HIP were sampled. VapA-
specific IgG and IgG subclasses were evaluated in all samples using an ELISA. Serum 
was collected from newborn foals either after commercial R. equi HIP was 
administered (n=97) or not (n=70). Serum was also collected from each mare. 
Administration of HIP significantly (p<0.001) increased VapA-specific IgGs in 
recipient foals, however, there was a marked variation in VapA-specific IgGs in foals 
receiving the same product. VapA-specific IgGs were significantly different (p<0.001) 
between products and varied between lots, with coefficients of variation ranging from 
17 to 123%.  These results may explain previously reported disparities in HIP efficacy.  
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Introduction 
Rhodococcus equi (R. equi), a gram-positive facultative intracellular pathogen, 
is the most devastating cause of pneumonia in foals between 3 weeks and 5 months of 
age 
1,87
. Due to its worldwide distribution, this disease has a major financial impact on 
the horse industry 
2
. Because of the absence of a vaccine to prevent R. equi infection, 
intravenous administration of R. equi specific hyperimmune plasma (HIP) shortly after 
birth is commonly practiced to reduce disease incidence or severity. This procedure 
may be repeated 4-8 weeks later 
48
. The efficacy of this approach remains controversial 
53,54,113
. Likewise, the protective component of R. equi HIP remains uncertain 
53
. 
Virulent R. equi carries a large virulence plasmid with a gene encoding for different 
virulence-associated proteins (VapA, VapC to H). The vapA gene encodes for a 
temperature inducible surface-expressed lipoprotein, which is necessary for R. equi 
survival inside de macrophage 
11,114
. Anti-VapA antibodies are thought to increase 
opsonization of R. equi by phagocytes 
51,61
. Indeed, in vitro opsonization of R. equi with 
immune serum enhanced phagolysosomal fusion and killing by macrophages 
61
.  
Three R. equi HIP products licensed by the USDA for the aid in prevention or 
moderation of R. equi pneumonia. Other products are also available for this purpose.  
While R. equi HIP appeared to be effective in some field studies 
48-50
 and after 
experimental challenge 
51,52
, others studies showed no positive effect 
53,54,113
. The 
reasons for these disparate results are unclear. Differences in study design, clinical 
outcome assessments, and timing of administration could explain the variability in the 
reported efficacies. Extrapolation of experimental challenge data to natural disease is 
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complicated by the variations in dosages and ages of foals used. Moreover, variability 
in the plasma products and their distribution in the foals could affect the outcomes.     
Therefore, the objectives of this study were: (1) to evaluate the distribution of 
VapA-specific IgG and IgG subclasses in commercially available R. equi HIP and (2) 
to evaluate VapA-specific IgG and IgG subclasses in foals after administration of 
different R. equi HIP.  
 
Materials and methods 
 
VapA purification, source of reference control sera and ELISA – see Chapter 3 
 
R. equi HIP 
 The uniformity of VapA-specific IgG and IgG subclasses in 4 commercially 
available R. equi HIP namely: ImmunoGlo
a
, ReSolution
a
, EquiplasREA
b
 and 
PneumomuneRe
c
 was evaluated by testing 3 different lots of each plasma product. The 
plasmas were thawed following manufacturer’s instructions and each bag was mixed 
well prior to analysis by ELISA.   
 
Serum 
Sera were obtained from mare and foal pairs at farms that routinely 
administered 1L of R. equi HIP to all foals within 24h of birth because of a history of 
rhodococcal pneumonia and from a farm without a history of disease and therefore did 
not use HIP. All mares and foals in a given farm were sampled. Mares were bled at the 
time of foaling. Foals were included if they had adequate passive transfer. All foals on 
the same farm received the same R. equi HIP product. Mares and foals were bled by 
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venipuncture and serum samples were archived at -20°C for batch analysis. All foals 
used in this study were born between January and May.  
 
Statistical analysis
 
Data were analyzed using a commercial software
d
. VapA-specific IgG 
subclasses, expressed as ELISA units (EU), were compared using one-way ANOVA or 
Kruskal-Wallis one-way ANOVA on ranks. Multiple comparisons were performed 
using Dunn’s or Holm-Sidak methods, respectively. Significance was set at p<0.05.  
 
Results 
 
R. equi HIP 
There were no significant differences between R. equi HIP products in terms of 
IgG (p=0.54) or IgGb (p=0.21) content. There was a significant (p=0.008) difference in 
VapA-specific IgGa between the plasmas. ReSolution had significantly more VapA-
specific IgGa (p<0.05) than EquiPLasREA and PneumomuneRe, but it was not 
different from ImmunoGlo. VapA-specific IgG(T) was extremely low in all products, 
though ReSolution had more IgG(T) than PneumomuneRe (p=0.016) (Figure 4.1).  
 
  
 
61 
 
 
Figure 4.1 (right) VapA-specific IgG, IgGa, IgGb and IgG(T) (left) in 3 different lots of 
each R. equi HIP. The horizontal lines within each box plot correspond to each of the 3 
bags of HIP tested for each company. R. equi HIP with different letters are different 
from each other at p<0.05 
 
The amount of variation between lots for each of the R. equi HIP varied 
amongst the products tested. Overall, ReSolution had the lowest variation and 
PneumomuneRe
 
the highest (Table 4.1). 
 
Table 4.1 Coefficient of variation (%) for VapA-specific IgG, IgGa and IgGb in 
different commercial R. equi HIP. 
  CV%-IgG CV%-IgGa CV%-IgGb CV%-IgG(T) 
EquiplasREA 74.9 57.8 109.7 10.8 
PneumomuneRe 123.8 106.6 112.9 7.3 
ReSolution 17.2 27.8 35.7 19.8 
ImmunoGlo 33.4 44.8 91.2 3.4 
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Mares and foals 
A total of 97 mare and foal pairs from 5 different farms that routinely used R. 
equi HIP were evaluated. Mares (n=48) and foals (n=70) from a farm that did not use R. 
equi HIP were included as controls. As expected, the foals receiving R. equi HIP had 
significantly (p<0.001) higher VapA-specific IgGs than their mothers and foals that did 
not received plasma.(Figure 4.2) VapA-specific IgG(T) was not evaluated after R.equi 
HIP administration due to the overall low amount present in each of the products. 
 
 
Figure 4.2 VapA-specific IgG (top), IgGa (middle) and IgGb (bottom) in mares at the 
time of foaling, foals 24h after administration of R. equi HIP and foals that didn’t 
receive any plasma 24h after birth. The horizontal line within the box represents the 
median and the ends of the box represent the 75th and 25th quantiles. The whiskers 
represent the upper and lower data points. The asterisk (*) indicates significant 
differences (p<0.05). 
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Administration of the different R. equi HIP to the foals resulted in significant 
differences in VapA-specific IgG, IgGa and IgGb (p<0.001).(Figure 4.3) VapA-specific 
IgG(T) in the foals was not evaluated after R.equi HIP administration due to the overall 
low amount present in each of the products. 
 
 
Figure 4.3 VapA-specific IgG (top), IgGa (middle) and IgGb (bottom) in foals 24h after 
administration of different R. equi HIP products. Un-ID 1 and 2 refer to R. equi HIP 
products whose source was not reported by the farm. The No HIP foals were untreated. 
The horizontal line within the box represents the median and the ends of the box 
represent the 75
th
 and 25
th
 quantiles. The whiskers represent the upper and lower data 
points. Treatment groups with different letters are different from each other at p<0.05 
 
As seen in Figure 4.3, a large variation in VapA-Specific IgG and IgG 
subclasses was observed in foals receiving the same R. equi HIP product (Table 4.2). 
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Table 4.2 Coefficient of variation (%) for VapA-specific IgG, IgGa and IgGb in foals 
after R. equi HIP administration. The numbers shown are the result of the total variation 
after 15% was subtracted to account for the variation of the ELISA. 
 
IgG-CV (%) IgGa-CV (%) IgGb-CV (%) 
PneumomuneRe 73 41 132 
ReSolution 18 41 70 
ImmunoGlo 46 65 43 
Unidentified-1 151 113 133 
Unidentified-2 64 94 95 
 
Discussion 
The rationale behind using HIP is to provide foals with R. equi-specific IgG, 
along with other factors, which may enhance the humoral effector mechanisms against 
this bacterium 
58
. In this regard, IgG is the best known opsonin and acts on the initial 
step of pathogen clearance 
67
. Thus, opsonising IgGs promote R. equi phagocytosis and 
killing in vitro 
65,66
. Likewise, R. equi HIP increased the oxidative burst activity of 
neutrophils and macrophages and the release of the proinflammatory cytokine TNF-α 
from macrophages in a dose dependent manner in vitro 
63
. VapA-specific antibodies, in 
particular, have been shown to be important in adult horses 
75
, mice 
115
 and foals 
51
. As 
expected, foals that received R. equi HIP had significantly more VapA-specific IgGs 
than untreated foals. Surprisingly, there was a large variation in VapA-specific IgG and 
its subclasses in foals receiving the same R. equi HIP product. Even when the inter-
assay variability of the ELISA test was taken into account, the CV between the foals 
remained large. Likewise, though body weights were not available for this study, 
difference in foal size is low in thoroughbred 
116
 and unlikely to be the cause of the 
differences seen here. Other unknown factors might account for the variability between 
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foals such as differences in the protocol for HIP administration between farms. 
However, plasmas were kept in the freezer until administration, thawed following 
manufacturer’s instructions and mixed before administration by the farm veterinarian. 
Thus, differences within HIP products seem the more likely explanation. Indeed, the 
amount of variation observed when different lots of the four R. equi HIP products were 
evaluated was larger in some products than in others and reflected that seen in foals 
following plasma administration. Furthermore, some of the foals that received R. equi 
HIP had low amounts of VapA-specific IgGs that were similar to untreated foals. 
Consistent with other reports 
66
, mares also had an overall low level of VapA-specific 
IgGs. This likely reflects the low numbers of R. equi in their environment.  While this 
low exposure resulted in a minimal antibody response in the mares, it was sufficient to 
cause disease in foals on these farms. Indeed, low numbers of R. equi have been shown 
to cause pneumonia in young foals after experimental challenge 
106
. In the farms 
included in our study, diagnosis of R. equi pneumonia was based on clinical signs, age 
of the foal, thoracic ultrasonography and response to treatment. While this is common 
practice in many farms 
117
 the lack of a definitive diagnosis limits the ability to evaluate 
the significance of the variations detected in VapA-specifc IgG subclasses or the 
protective effect of HIP.  
There were also significant differences in VapA-specific IgG and IgG 
subclasses in each product. Since the immunoglobulin subclass required for protection 
against R. equi infection remains unknown, the clinical significance of this finding is to 
be determined. However, the described protective activity of antibodies is a function of 
their subclass. Thus, the use of R. equi HIP that contains inadequate quantity or quality 
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of VapA-specific antibodies could explain those instances when HIP fails to prevent R. 
equi infection.   
In conclusion, the variation seen in VapA-specific IgGs of R. equi HIP products 
persists in foals after these products are administered. The variation is worse in some 
products than in others. Given the lack of an effective R. equi vaccine 
118,119
, the cost of 
R. equi HIP administration and its potential side effects, more work is needed to 
identify the protective nature of HIP and to optimize its production to ensure better 
product uniformity. 
 
 
 
 
 
 
 
Copyright © Macarena G Sanz 2014 
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CHAPTER 5 
VAPA-SPECIFIC IgG AND IgG SUBCLASSES RESPONSE AFTER NATURAL 
INFECTION AND EXPERIMENTAL CHALLENGE OF FOALS WITH 
RHODOCOCCUS EQUI  
 
Summary 
Rhodococcus equi is a common cause of pneumonia in young foals worldwide, 
however, the humoral response of foals to this disease remains poorly defined. VapA, a 
bacterial lipoprotein, is the critical factor that differentiates virulent from non-virulent 
R. equi. Therefore, the objectives of this study were to evaluate changes in VapA-
specific IgG and IgG subclasses after experimental challenge of neonatal foals, as well 
as after natural exposure and infection of thoroughbred foals on a breeding farm.  
Two groups of foals were evaluated: (1) Foals experimentally challenged with 
R. equi at 1 (n=18), 2 (n=4) and 3(n=6) weeks of age that were housed with confirmed 
naturally infected (n=7) and not infected (n=3) foals. These foals were bled weekly for 
a period of 8 weeks. (2) Thoroughbred foals routinely given 1L of R. equi 
hyperimmune plasma (n= 106) and foals that did not receive plasma (n=35) were bled 
at birth and monthly thereafter for a period of 4-5 months. Cases of rhodococcal 
pneumonia amongst these foals were recorded.  
Following birth, VapA-specific IgGs significantly (p<0.05) decreased in all 
foals. Both VapA-specific IgGa and IgG(T) also decreased following birth and then 
significantly increased (p<0.05) in those foals that developed rhodococcal pneumonia 
after experimental and natural infection.  However, VapA-specific IgGa also increased 
over time after exposure to R. equi in foals that remained clinically normal.  As a result, 
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VapA-specific IgG(T) may be more useful in identifying foals affected with 
rhodococcal pneumonia 
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Introduction 
Rhodococcus equi is an important pathogen worldwide that causes severe 
pneumonia 
120
 and a variety of extrapulmonary lesions in young foals 
25,26
. In contrast, 
adult horses are resistant to R. equi infection unless they are immunocompromised.  
Nevertheless, little is known about the unique susceptibility of foals to this infection. 
Protective immunity to R. equi likely involves innate, humoral and cell-mediated 
immune responses 
58,66,121
. Antibodies, especially IgG, are important because of their 
opsonic activity 
51,61,62,122
 since entry of R. equi into macrophages mediated by Fc 
receptors leads to enhanced bacterial killing 
17,51,64,122
. Immunoglobulin G against R. 
equi increased over time in foals beginning at 3-5 weeks of age as a result of natural 
exposure 
77,78
. Oral and intratracheal inoculation of foals also resulted in an increase in 
IgG 
57
. None of these studies evaluated IgG subclasses of which there are multiple in 
the horse with differing abilities to activate complement and stimulate a respiratory 
burst from peripheral blood leucocytes 
69
.  To date, little is known about the protective 
role these IgG subclasses play in R. equi infection.  Though previous studies also failed 
to discount antibody responses to non-virulent R. equi, subsequent assays measuring 
IgG to VapA, a surface lipoprotein of R. equi required for virulence 
11,114
, allowed 
differentiation between virulent and non-virulent bacteria.  Nevertheless, there remains 
uncertainty regarding the protective IgG response to R. equi.  Thus, in adult horses 
experimentally challenged with R. equi various subclass responses have been reported 
including an increase in VapA-specific IgGa, 
62
 IgGb 
74
 or both IgGa and IgGb 
75
.  In 
intrabronchial-infected foals there was an increase in VapA-specific IgGa and IgGb 
74
. 
Whereas foals with naturally occurring rhodococcal pneumonia produced significant 
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amounts of VapA-specific IgG(T) 
62
. In contrast, a VapA-specific IgG(T) response was 
not seen after natural exposure in adult horses or healthy foals 
62
.  However, VapA-
specific IgG(T) was significantly higher when a larger R. equi inoculum was used to 
challenge neonatal foals 
47
.  Recently, VapA-specific IgG(T) was shown to be a good 
indicator of rhodococcal pneumonia in a challenge of neonatal foals using a low dose of 
R. equi which more accurately resembled natural infections 
106,123
.  While early R. equi 
studies proposed that IgG(T) could not activate complement and therefore was an 
undesired response to infection 
62
, it has since been shown to be the most potent 
complement activator in horses 
69
. Furthermore, Vap-specific IgG(T) increased after 
oral immunization with virulent R. equi that successfully protected foals 
24
.  
It is clear from the studies described above that further research needs to be 
conducted in order to clarify the role of IgG and IgG subclasses in the response of foals 
to R. equi.  Also, an antibody response which differentiates R. equi exposure from 
infection remains to be defined.  Such knowledge is essential for the development of 
preventive and diagnostic methods. Therefore, the objectives of this study were to 
evaluate changes in VapA-specific IgG and IgG subclasses after experimental 
challenge of neonatal foals, after natural exposure and after natural infection.  
 
Materials and methods 
 
VapA purification, source of reference control sera and ELISA – see Chapter 3 
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Serum samples   
Sera from two populations of foals were included in this study: neonatal foals 
experimentally challenged with R. equi and foals naturally exposed with or without 
clinical signs of rhodococcal pneumonia. All sera were archived at -20°C for batch 
analysis.   
The challenged foals were intratracheally infected at 1, 2 or 3- weeks of age 
(n=18, n=4 and n=6 respectively) with 10
3
 cfu/foal of R. equi (206
+
UKVDL). The 
challenge was performed for a previous study 
106
 in which every foal was bled before 
challenge and weekly thereafter until development of clinical signs of pneumonia or 
until foals were 8 weeks of age.  Another group of foals (n=10), that could not be 
challenged due to partial failure of passive transfer (400 mg/dl<IgG < 800 mg/dl), was 
housed in the same pasture as the challenged foals.  Of these foals, those that developed 
ultrasonographic and macroscopic lung lesions consistent with rhodococcal pneumonia 
and had positive lung tissue culture for R. equi were considered naturally infected 
(n=7).  Foals that remained healthy thorough the duration of the study, did not develop 
ultrasonogoraphic or macropscopic pulmonary lesions and had negative lung tissue 
cultures, were considered not infected (n=3). All foals were bled at birth and weekly 
thereafter for 8 weeks.  
Sera from newborn foals at a thoroughbred farm that routinely administered 1L 
of R. equi hyperimmune plasma (HIP) to all foals within 24h of birth  (n=106) and from 
farms that did not administer HIP (n=35) were used. Foals were included if they had 
adequate passive transfer (IgG>800mg/dl) and were bled by venipuncture 24h after 
birth or after HIP administration and monthly thereafter for a period of 4-5 months. A 
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presumptive diagnosis of R. equi pneumonia was made if foals >1m of age developed 
clinical signs of pneumonia (fever, lethargy, increased respiratory rate and effort, nasal 
discharge, cough), had ultrasonographic lesions consistent with consolidation or 
abscessation of the lung and responded to antimicrobial treatment for R. equi (rifampin 
and azithromycin). A definitive diagnosis, by culture or PCR and cytology of a 
transtracheal wash, was not performed. 
 
Statistical analysis 
Distribution of each data set was assessed using the Shapiro-Wilk normality 
test. When variables were not Gaussian distributed non –parametric tests were used. To 
evaluate changes over time, repeated measures ANOVA on ranks was used. To 
compare ELISA unit (EU) results between populations, Kruskal-Wallis one-way 
ANOVA on ranks and Mann-Whitney U tests were used. Pairwise multiple 
comparisons were performed using the Dunn’s or Holm-Sidak methods. The analysis 
was performed 2-tailed and significance was set at p<0.05. All data were analyzed 
using a commercial software
 a
. 
 
Results 
 
VapA-specific IgGs after experimental challenge: There was a significant 
(p<0.05) decrease in all VapA-specific IgGs the first 2-4 weeks after birth in foals 
challenged at 1, 2 or 3 weeks of age (Figures 5.1-3). After challenge of 1-week old 
foals, a significant (p=0.003) increase was only observed for IgG(T) (Figure 5.1). 
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VapA-specific IgGa increased over time, however it did not reach statistical 
significance (p=0.054). 
 
Figure 5.1 From top to bottom: VapA-specific IgG, IgGa, IgGb and IgG(T) expressed 
as ELISA units (EU) over time after intratracheal challenge of 1-week-old foals (n=18) 
with 10
3
 cfu/foal of R. equi. The horizontal line within the box represents the median 
and the ends of the box represent the 75
th
 and 25
th
 quantiles. The whiskers represent the 
upper and lower data points. The asterisk (*) indicates significant differences with pre-
challenge (w1) values (p<0.05)  
 
VapA-specific IgGa significantly increased over time after both, 2 and 3-week-
old foals were challenged (p<0.05 and p=0.009 respectively) (Figures 5.2 and 5.3). No 
other changes were seen in 2-week-old thorough the study whereas in the 3-week-old 
foals there was a significant effect (p=0.028) of time on VapA-specific IgG 
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concentration and a significant (p=0.002) increase in VapA-specific IgG(T) (Figure 5. 
3). 
 
Figure 5.2 From top to bottom: VapA-specific IgG, IgGa, IgGb and IgG(T) expressed 
as ELISA units (EU) over time after intratracheal challenge of 2-week-old foals (n=4) 
with 10
3
 cfu/foal of R. equi. The horizontal line within the box represents the median 
and the ends of the box represent the 75
th
 and 25
th
 quantiles. The whiskers represent the 
upper and lower data points. The asterisk (*) indicates significant differences with pre-
challenge values (p<0.05) 
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Figure 5.3 From top to bottom: VapA-specific IgG, IgGa, IgGb and IgG(T) expressed 
as ELISA units (EU) over time after intratracheal challenge of 3-week-old foals (n=6) 
with 10
3
 cfu/foal of R. equi. The horizontal line within the box represents the median 
and the ends of the box represent the 75
th
 and 25
th
 quantiles. The whiskers represent the 
upper and lower data points. The asterisk (*) indicates significant differences with pre-
challenge values (p<0.05)  
 
VapA-specific IgGs in confirmed naturally infected foals: VapA-specific IgG 
(p=0.03) and IgGb (p=0.004) significantly decreased over time in naturally infected 
foals. VapA-specific IgGa significantly (p=0.006 increased over time towards the end 
of the study. There was also a significant (p=0.027) increase of VapA-specific IgG(T) 
over time (Figure 5.4). 
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Figure 5.4 From top to bottom: VapA-specific IgG, IgGa, IgGb and IgG(T) expressed 
as ELISA units (EU) over time in foals naturally infected with R. equi. The horizontal 
line within the box represents the median and the ends of the box represent the 75
th
 and 
25
th
 quantiles. The whiskers represent the upper and lower data points. The asterisk (*) 
indicates significant differences with values obtained the first week of life (p<0.05).  
 
VapA-specific IgGs in negative foals: Significant changes over time were not seen in 
VapA-specific IgG (p=0.639), IgGa (p=0.676), IgGb (p=0.716) or IgG(T) (p=0.484) in 
unchallenged foals that remained negative thorough the study.  
 
VapA-specific IgGs in naturally exposed and presumptively infected Thoroughbred 
foals: Rhodococcal pneumonia was diagnosed in 10 foals (10.4%) that received HIP 
and in 5 (14.2%) that HIP was not administered. The median (range) age at the time of 
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diagnosis was 62 days (42-91d) in foals given HIP and 119 days (35-150d) in the 
untreated foals.   
There were no significant differences in VapA-specific IgG (p=0.78), IgGa 
(p=0.91), IgGb (p=0.84) or IgG(T) (p=0.48) immediately after HIP administration 
between foals that remained healthy and those that later developed rhodococcal 
pneumonia.  All VapA-specific IgGs significantly (p<0.001) decreased over time after 
HIP administration in foals that remained healthy thorough the study period. Similarly, 
VapA-specific IgG and IgGb significantly (p=0.002) decreased in pneumonic foals; 
though IgGa remained unchanged and IgG(T) increased over time but did not reach 
statistical significance (p=0.06) (Figure 5 A-D). 
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Figure 5.5 VapA-specific IgG (A), IgGa (B), IgGb (C) and IgG(T) (D) in foals that 
develop pneumonia (
____
) or remained healthy (----) after HIP administration. The 
horizontal line represents the mean and the whiskers are error bars. Each error bar was 
constructed using the 95% CI of the mean. Time points with different letters are 
significantly different between themselves in both groups. The asterisk (*) indicates 
significant differences with values obtained at birth in healthy foals. The numeral (#) 
indicates significant differences with values obtained at birth in pneumonic foals 
(p<0.05). 
 
There were no significant differences (p>0.05) in VapA-specific IgG, IgGa, 
IgGb or IgG(T) at birth between foals not given HIP and remained healthy and those 
that later developed rhodococcal pneumonia. Foals that remained healthy throughout 
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the study had no significant changes in VapA-specific IgG (p=0.29), IgGa (p=0.4), 
IgGb (p=0.5) or IgG(T) (p=0.4) over time. While VapA-specific IgGa (p=0.25) and 
IgGb (p=0.07) did not change over time in foals that developed rhodococcal 
pneumonia, VapA-specific IgG (p=0.006) and IgG(T) (p=0.006) significantly increased 
in pneumonic foals thorough the study period (Figure 5.6 A-D). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
80 
 
 
 
Figure 5.6 VapA-specific IgG (A), IgGa (B), IgGb (C) and IgG(T) (D) in foals that 
develop pneumonia (
____
) or remained healthy (----) in farms where HIP was not 
routinely administered. The horizontal line represents the mean and the whiskers are 
error bars. Each error bar was constructed using the 95% CI of the mean. Time points 
with different letters are significantly different between themselves in both groups. The 
numeral (#) indicates significant differences with values obtained at birth in pneumonic 
foals (p<0.05). 
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Discussion 
A better understanding of the humoral immune response of foals to R. equi is 
necessary in order to develop new diagnostic tests and preventive measures. To date, 
little is known about IgG and IgG subclass responses to R. equi infection in foals. Here, 
VapA-specific IgG subclass responses were assessed in experimentally challenged, 
naturally exposed, and infected foals.  As expected, all foals showed a decreased in 
VapA-specific IgGs during the first 2-4 weeks of life. This is consistent with the normal 
decay of antibodies that occurs after passive transfer of immunoglobulins through 
colostrum 
70
. The VapA-specific IgG decrease was not as marked in foals diagnosed 
with partial passive failure of transfer, likely owing to their overall lower plasma 
antibody concentration.   
Experimental challenge of neonatal foals using a low dose of R. equi, which has 
been shown to result in slow, progressive disease similar to that of natural infection 
106
, 
resulted in a significant increase in VapA-specific IgGa and IgG(T) over time. Though 
VapA-specific IgGa increased over time after challenge of 1-week-old foals, it did not 
reach statistical significance (p=0.054).   This was due to the fact that endogenous 
production of IgGa is not optimal until foals are 1m of age or older 
70
 and half of the 
foals were euthanized early because they developed clinical signs.  Should this group of 
foals been followed for a longer period of time, a significant increase would likely have 
been observed. Foals challenged at 2 and 3 weeks of age had a significant increase in 
VapA-specific IgGa, indicating an enhanced ability to respond to this pathogen. Foals 
are highly susceptible to rhodococcal pneumonia if challenged at 1 week of age but 
developed resistance when challenged at 3 weeks of age 
106
, consistent with a 
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developing resistance mechanism. A significant increase in VapA-specific IgG(T) was 
not seen in foals challenged at 2-weeks of age probably because only 4 foals were 
included in this group, 2 of which were euthanized before they reached one month of 
age as they developed clinical signs of pneumonia and synthesis of IgG(T) begins when 
foals are somewhat older 
70
. Similarly, VapA-specific IgGb did not increase after 
experimental challenge in any of the foals as production of IgGb does not begin until at 
least 8 weeks of age 
70
. 
Comparably to that seen after experimental challenge, there was a significant 
increase over time in VapA-specific IgG(T) after natural infection of foals with R. equi. 
While an increase in IgG(T) over time was seen in pneumonic foals given HIP, this was 
not statistically significant.  One explanation may be that some of the foals were 
misdiagnosed since culture and cytology of a TTW was not performed to obtain a 
definitive diagnosis of R. equi. Indeed, 3 foals diagnosed as having rhodococcal 
pneumonia showed no increase in VapA-specific IgGs over time, and therefore likely 
had pneumonia of other origin. When these 3 foals were removed from the analysis 
(data not shown), a significant increase in VapA-specific IgG(T) was observed over 
time.   
In general, VapA-specific IgG(T) significantly increased over time in foals that 
developed clinical rhodococcal pneumonia while it remained lower in healthy foals. 
This supports previous work showing that VapA-specific IgG(T) has high sensitivity 
and specificity in detecting rhodococcal pneumonia in foals (Sanz et all, EVJ in press). 
VapA-specific IgGs did not increase in control foals that were confirmed negative by 
ultrasound and at necropsy.  However, it did in healthy thoroughbred foals, though this 
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was not statistically significant.  It has been previously shown that VapA-specific IgG 
does increase over time in healthy foals as a result of natural exposure to R. equi 
84
. 
 Routine thoracic ultrasonography was not performed in the thoroughbred foals, 
hence subclinical disease cannot be ruled out.  Indeed, the majority of foals that 
develop pulmonary lesions resolve them without the need for treatment 
32
.  
In conclusion, the early response to R. equi infection is characterized by an 
increase in VapA-specific IgGa and IgG(T) that is seen as soon as 4-5 weeks of age. 
This increase in VapA-specific IgG(T) is more specific for R. equi infection as IgGa 
also increases significantly as a result of environmental exposure, hence its evaluation 
may become useful to differentiate rhodococcal pneumonia from other bacterial 
pneumonias affecting young foals. Further research is needed to evaluate the role of 
VapA-specific immunoglobulins in subclinical cases, in particular more work is needed 
to evaluate the use of VapA-specific IgG(T) as a possible marker for disease. The 
similarities observed between the IgG response of foals after experimental challenge 
and natural infection confirms that the use of a low dose of R. equi to challenge foals is 
an appropriate model to study the humoral response to this disease. 
Copyright © Macarena G Sanz 2014 
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CHAPTER 6 
CONCLUSIONS, FUTURE DIRECTIONS AND LIMITATIONS 
 
While R. equi pneumonia is a common cause of pneumonia with devastating 
consequences for the equine industry, much remains unknown about the reasons for the 
foal’s unique susceptibility to this pathogen. As a result, attempts to develop 
prophylactic methods have not been successful. The development of the unique 
neonatal foal model described here, that results in slow progressive disease and 
regression in approximately 50% of the foals, provides a new tool to advance the 
understanding of the immune response and the individual susceptibility of foals to R. 
equi. While is accepted that foals are infected with R. equi shortly after birth; the 
duration of their susceptibility has not been well quantified. This model developed here 
provided the means to systematically evaluate the effect of age on susceptibility and 
showed that the window for disease occurs within the first month of age. These findings 
have a direct implication on the future approaches to prophylaxis.  
Diagnosis of the early stage of R. equi pneumonia remains a challenge for the 
equine practitioner. Culture and cytology of lung fluid are not useful until foals are 
clinically ill. Thoracic ultrasonography over-estimates the prevalence of disease and 
results in excessive antimicrobial use. The results on chapters 3 and 5 identify VapA-
specific IgG(T) as a potential marker for disease after the ELISA was validated. Its 
measurement in foals showing clinical signs of pneumonia may provide an innovative 
tool to confirm or rule out R. equi as a causative agent, especially as this will only 
require a serum sample instead of the more invasive TTW for culture. The possibility to 
rule out R. equi with a simple test will aid in the decrease of macrolide use in foals and 
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the development of resistance to this drug, something that is currently a concern among 
equine practitioners. More research is needed to evaluate this immunoglobulin’s ability 
to predict clinical disease and its correlation with the degree of pneumonia in both, 
clinical and subclinical foals.  
This study evaluated, for the first time, the VapA-specific IgG status of a group 
of Icelandic horses and found that horses in Iceland are not exposed to virulent R. equi, 
probably a result of low or absent amounts of this organism in the environment. The 
northern location of this island with its cold weather and the fact that in 982 AD the 
Icelandic parliament passed laws prohibiting the importation of horses into Iceland are 
factors that contribute to the lack of rhodococcal cases reported in this country. The 
availability of this naïve population provides a valuable source of true negative animals 
to establish assay baselines. Using these horses, an ELISA for VapA-specific IgG and 
IgG subclasses were validated and used to follow the changes that occur in these 
antibodies after natural exposure, natural infection and experimental challenge. This 
knowledge will be helpful in evaluating responses to vaccination or other prophylactic 
measures. The ELISA was also used to detect the surprisingly high variability of VapA-
specific IgGs in commercial HIP, which was reflected in the variability seen in foals 
after HIP administration. Such variability may explain controversial reports on the 
efficacy of HIP products in prevention of R. equi pneumonia. Further work is needed 
evaluating HIP production and processing to improve product quality and uniformity.  
A limitation of this work was the use of a single R. equi strain in the 
experimental challenge model. The strain selected originated from a field case of 
rhodococcal pneumonia near Lexington, KY, hence it is considered of clinical 
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relevance. Another limitation is the small number of foals used in each experiment, a 
common theme in equine research because of cost and animal availability. 
Acknowledgment of this limitation is important for interpretation of the results reported 
here. Lastly, only VapA-specific IgG subclasses were evaluated in the HIP study. At 
this point, the protective component, if any, of HIP remains unknown; however, VapA 
antibodies are considered important. More field work is needed in this area to evaluate 
the observed variability in HIP lots and its impact in protection against R. equi. 
Overall, this body of work has resulted in a consistent challenge model that 
closely resembles natural disease. It has also confirmed the effect of age in foal 
susceptibility and has been effective in describing the VapA-specific IgG and IgG 
subclass response of foals to R. equi, not only after infection but also after natural 
infection. As such, this work will aid future research on prophylactic strategies and 
their timing, which hopefully will result in a better knowledge of this common but still 
poorly understood condition.  
 
 
 
 
 
 
Copyright © Macarena G Sanz 2014 
  
  
 
87 
 
APPENDIX 
 
Manufacturers’ details – Chapter 3 
 
a
 Amersham Pharmacia Biotech, Pittsburgh, PA, USA. 
b
 Bio-Rad, Philadelphia, PA, USA.  
c
 MgBiologics, Ames, IO, USA. 
d
 Plasvacc USA Inc, Templeton, CA, USA. 
e 
Thermo Scientific, Rochester, NY, USA.  
f
 Sigma Aldrich, St. Louis, MO, USA.   
g
 Jackson ImmunoResearch, West Grove, PA, USA. 
h 
Bethyl Laboratories, Inc, Montgomery, TX 77356 USA 
I 
Beckman Coulter, Brea, CA, USA. 
j
 KPL, Gaithersburg, MD, USA.  
k 
SigmaPlot, SPSS Inc., Chicago, IL, USA. 
 
Manufacturers’ details – Chapter 4 
 
a
 MgBiologics, Ames, IO, USA. 
b
 Plasvacc USA Inc, Templeton, CA, USA. 
c
 Lake Immunogenics Inc, Ontario, New York, USA. 
d.
SigmaPlot, SPSS Inc., Chicago, IL, USA. 
 
Manufacturers’ details – Chapter 5 
 
a
 SigmaPlot, SPSS Inc., Chicago, IL, USA. 
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Chapter 1 
Supplementary Table 1.1 Comparison of the original and current nomenclature for 
equine IgG subclasses.
68
  
Original Nomenclature Current Nomenclature 
IgGa IgG1 
IgGb IgG4 and IgG7 
IgG(T) IgG3 and IgG5 
IgGc IgG6 
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Chapter 2 
 
Supplementary Figure 2.1 Study design for foals challenged intratracheally with 
doses of R. equi ranging from 10
6
 to 10
2 
cfu/foals (top) and with 10
3
 cfu/foal at 
different ages (bottom). 
 
Supplementary Figure 2.2 One-cm
3
 tissue samples were obtained for bacterial 
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culture. Samples were routinely collected from the cranial lobe, cranio-ventral and 
dorsal border of the diaphragmatic lung lobe of each lung and from the accessory lobe 
(not in the picture) 
 
 
Supplementary Figure 2.3 Serial dilutions (not diluted to 1:10000) of the 
supernatant obtained after tissue homogenization plated onto TSAYE plates. Plates 
were incubated at 37 ºC for 48h and the number of colonies/g of tissue was then 
calculated. Colonies were observed for typical R. equi characteristics (large, mucoid 
colonies that developed a red pigment over a 72h period)  
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Protocol 2.1 - Preparation of R. equi inoculum for foal challenge  (Figures A 
and B) 
 
1.From -80C stock solution streak 2 TSAYE plates 
2.Incubate at 37ºC for 48h 
3.Take a single colony with a sterile loop and inoculate 4ml of TSBYE broth. Repeat 4 
times using different colonies. Gram stain colonies and evaluate colony morphology 
for characteristics (mucoid, large, pink) 
4.Incubate at 37ºC for 48h 
5.Evaluate OD600: ~0.38-0.44  
6.Select the broth with OD600 0.4 or closer. This is the broth that will be used for 
challenge. 
a- Perform 5 serial dilutions (1:10), plate 25 ul of the 10-5 and spread for bacterial 
counting, in duplicate. Incubate at 37ºC for 48h to evaluate purity of the culture 
and count colonies. 
To calculate the concentration of the broth:  
cfu counted (average of both plates) x 40 = cfu x10
-5
/ml 
b- Submit an aliquot to the UKVDL for PCR confirmation of R. equi and VapA 
c- The concentration of the broth with OD600 = 0.4 is 10
7
/ml (this is based on the last 
3 years of isolation, this has remained constant and we have done this weekly). 
Perform serial dilutions on PBS to obtain the desired concentration for challenge 
 
 
Figure A Frozen stock to broth stock 
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Figure B Challenge inoculum preparation, cfu count, VapA confirmation 
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Chapter 3  
Protocol 3.1 - VapA purification from Vap-containing E. coli  
 E. coli proliferation 
1. Scrape small amount (VAP)-containing E. coli cells’ glycerol stock onto one LB 
agar plate containing 100 ug/ml Ampicillin  
2. I  
3. Touch single colony and inoculate a 5 ml culture of LB broth containing 100 ug/ml 
Ampicillin [Repeat for total of 4(5 ml) cultures]  
4. Incubate for 5 hours in 50 ml conical tubes with lid slightly 
shaking at ~150 rpm  
5. Add 5 ml starter culture to 500 ml LB broth containing 100 ug/ml Ampicillin (One-
5 ml culture per 500 ml broth) (Culture minimum of three flasks)  
6. Incubate overnight 
loosened or with filter top on flask.  
7. Remove cultures from shaker. Check that OD600 is around 1.0. If culture has not 
 
8. Add IP (See 
page 106 of protocol for IPTG formulation)  
9. 
production. (150 rpm) 
10. Spin down cultures @ 7700g for 10 minutes. (or 2500g for 45-60 minutes at 4 )  
11. Pour off supernatant and remove a sample for analysis at a later time. 
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12. Resuspend the pellet in a total volume of 25 ml sterile PBS and place 25 ml in 50 
ml centrifuge tubes with lid slightly loosened into – freezer overnight (a 
freeze/thaw)  
13. Perform purifications using Purification of GST Fusion Proteins protocol (see 
below) 
 
II- Purification of GST (glutathione S-transferase) fusion proteins – VapA  
Day one 
Sonicate cells in centrifuge tubes for 30 sec pulses (x 4 times) keeping the samples on 
ice.  
1. Add Triton X-100 (20% stock solution) to make 1% (1 ml per 20 mls) (See page 
106 of protocol for formulation).  
a- Mix in the plate rocker gently for 30 min @ room temp.   
b- Spin @ 10,000 rpm for 10 min @ 4oC. 
2. Remove and save supernatant in 50 mL conical tube (aliquot a sample for SDS-
PAGE) (See pages 97-103) 
a. Pool supernatants.   
b. Suspend pellet in minimal PBS, pool and aliquot a sample for SDS-PAGE. (Only 
once at the beginning of the study) 
c. Filter supernatant (Steriflip 100 m vacuum flip filter- Millipore Cat no. 
SCNY00100). 
3. Add 3.5 ml of pre-washed Glutathione Sepharose beads* (mix with PBS in the 
column) to the 50ml supernatant to use the big column.  
4. *Pre-Washing procedure: (If using for the first time) 
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a- Pipette 1 ml of sterile PBS in column (Thermo disposable plastic columns with a 
filter disc-29920, 29922, and 29924) and add 1.33 ml of beads (75% slurry in 
ethanol).  
b- Remove cap and wash beads by running 10 ml through column. 
c- Cap off bottom and add 1ml PBS (50 % slurry), 2 ml total. 
d- Using a Pasteur pipette, add to the 50 mls of supernatant in the conical tube. 
e- Place parafilm on the top and bottom cap of the column to prevent drying. 
5. Incubate overnight with gentle mixing @ 4oC. (Fusion protein binds to beads) 
 
Day two (work at room temperature) 
1. Let the beads settle and add top portion to the column first (faster), and finally the 
beads in PBS. Collect a sample for SDS-PAGE.  
2. Wash beads gently twice (two columns full) with sterile cold PBS.  Cap bottom of 
the column. Collect a sample for SDS-PAGE 
3. Add 50 ul thrombin (GE Healthcare GST Gene Fusion System Handbook Chapter 
6) to 950 ul PBS and add to column. (Wrap parafilm around top and bottom caps of 
column) 
4. Incubate overnight (22 hours) @ room temperature with gentle mixing. (Thrombin 
cleaves protein).  
 
[Alternative method (faster)]:   
1. Spin beads in 50 ml conical tube at 4 oC at 2500-3000 rpm for 5-7 minutes, aspirate 
fluid off and add to column leaving beads in tube.) 
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2. Wash beads gently twice (two columns full) with sterile cold PBS.  Centrifuge as 
above between washes. 
3. After final wash, add beads to column, allow to drain, and cap bottom of the 
column. 
4. Add 50 ul thrombin (GE Healthcare GST Gene Fusion System Handbook Chapter 
6) to 950 ul PBS and add to column (i.e. 50 units per 1 ml of beads). Place parafilm 
around top and bottom caps of column. 
5. Incubate overnight (16 hours) @ room temperature with gentle mixing. (Thrombin 
cleaves protein). 
 
Day three  
1. Remove top and bottom caps and collect the protein (approx. 500 ul) into a small 
sterile tube. (Place on ice until ready to run Bradford, and then freeze at -80
o
C) 
Replace tip on bottom and lid on top of column. If beads become trapped in the lid, 
the protein will be removed in the next step.  
2. Add 2 mls of PBS to column and gently mix on tilt table for 30 min @ room 
temperature.  Collect eluate and place in a separate tube. Place on ice until ready to 
perform Bradford assay, then freeze at -80
o
C.  This portion usually needs to be 
concentrated (see comment below). 
3. Remove a sample of the eluate for SDS-PAGE (for verification of protein).  
Replace caps on column with sterile PBS to store in fridge until ready to clean and 
regenerate column, as below.) 
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If necessary, concentrate proteins using first the 30,000 NMWL filter, then filter flow 
through w/ 10,000 MWCO keeping retentate.  Centrifuge at 4
o
C for 5-20 minutes 
depending on volume at 3,000 g.  
 
Clean and regenerate column for further use: 
I. Remove GST from beads by adding 1 ml of glutathione elution buffer (See page 
108 for formula).  Mix for 10 min @ room temperature. 
II. Elute and wash several times with PBS. (Repeat twice saving eluate in separate 
tubes for Bradford analysis of protein amount, when initially checking protocol).  
III. Wash with 1 ml of 0.1M Tris HCl  + 0.5M NaCl, pH 8.5, Followed by (1 mL) 0.1M 
sodium acetate + 0.5M NaCl, pH4.5 (See pages 107-108 for formulas) 
IV. Repeat wash cycles 4 times, alternating buffers. 
V. Wash with 2 mls PBS. 
VI. Replace top and bottom caps, add 1ml PBS, and seal with parafilm. For long-term 
storage or further information regarding regeneration, refer to page 29 of the kit 
instruction booklet (GE Healthcare GST Gene Fusion System Handbook- Chapter 4 
batch purification). 
Run Bradford assay to quantify proteins. (See page 105) Store at -80
o
C until ready to 
use. 
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SDS-PAGE gel with Coumassie Blue staining 
Sensitivity=.1-.5 ug (50-100 ng/band)\ 
For purified sample- want 10 ug, for other samples 50-100 ug, adjust volume w/PBS 
Laemmli Sample buffer-2x sample buffer 475 ul + 25 ul 2-me ( -mercaptoethanol) 
 
For 30 ul volume for 18 well gel- 15 ul of sample+ 15 ul 2x sample buffer w/2-me 
For 40 ul volume for 12 well gel- 20 ul of sample+ 20 ul 2x sample buffer w/2-me 
1. Mix well 
2. Heat to 95oC for 5 minutes 
3. Place on ice to cool 
4. Centrifuge several seconds (5 min at 6.0 rcf) 
5. Place at -80 oC for storage if not using immediately  
 Marker:     1μL + 20 μL reduced Laemmli buffer; 
                   Heat to 95
o
C for 5 minutes; 
                   Place on ice to cool; 
                   Load 10 μL/ well. 
Molecular Weight: 200 KD; 116.2; 97.4; 66.2; 45; 31; 21.5; 14.4; 6.5.  
Purchase a pre-poured gel  
Biorad Criterion 4-20% Tris-Hcl gel with 14 or 18 wells 
(Biorad Labs, 2000 Alfred Nobel Dr. Hercules, CA  94547) 
 
Loading the gel 
1. Remove the white tab from the bottom of the gel.   
2. Carefully remove the comb. 
  
 
99 
 
3. Use a syringe with a needle attached to flush the wells with running buffer just 
before loading to get rid of any unpolymerized polyacrylamide that may seep in. 
4. Insert the gel into the apparatus with the numbers facing outward. 
5. Pour Tris-glycine electrophoresis buffer into the upper and lower chambers. Fill to 
within several mm of top and to the second line in the bottom chamber. Make 500 
ml of running buffer by adding 100 ml of 5X stock to 400 ml Ultrapur H20. 
6. When loading the gel, load something (1X loading buffer in blank lanes) in every 
lane and the dye will migrate more evenly.(Use SDS Standard, Broad Range, 
catalog # 161-0317 as size marker)-molecular weight markers 
7. Start large thin gels at a constant current of 15 mA/gel for 10 minutes then increase 
to 20 mA/gel for the remaining time. (Check in 1½ hrs)  
 
Where you stop the gel will depends on how big the smallest protein is that you want to 
visualize. It should take about 2 1/2 – hours for a large, thin gel to run. A thick gel 
could take 6 - 7 hours. Run minigels at 15 mA. It should take about an hour to run. 
 
Staining the gel 
1. Turn off machine and remove the lid 
2. Pour off buffer from top chamber 
3. Use lid to break open the gel chamber 
4. Cut off the wells 
5. Pull gel off from the bottom by lifting center with forceps and running fingers to 
edges (Bottom is tougher than the top) 
6. Place gel in plastic lid and cover with Coumassie Blue stain. 
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7. Place on rocker and rock (setting 3) for ~45 mins. 
8. When finished, pour Coumassie Blue back into container for reuse. 
9. Move gel to a sealable Tupperware container. 
10. Add wash (7% Acetic Acid, 10% methanol- 70 ml AA + 100 ml methanol, bring to 
1L with ultrapur H20). 
11. Add a sponge to the top of the liquid (helps to bind the Coumassie Blue) 
12. Place on gentle rocker.   
13. Change wash ~every 30 mins until you go home. 
14. Allow to rock (wash) overnight 
 
Tris-Glycine Electrophoresis Buffer 
5X Stock: 
15.1 g Tris base + 94 g glycine + 900 ml H2O 
Then add 50 ml of 10% electrophoresis-grade SDS, and adjust volume to 
1000 ml with H2O 
 
For buffer to add to the apparatus: 
Make 500 ml by adding 100 ml of 5X stock to 400 ml Ultrapur H20 
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To visualize/photograph gel: 
After overnight wash, place gel on saran wrap. Place on white light on transilluminator 
to visualize. Then move to transilluminating reader. Settings: 10 ms, no filter, adjust as 
necessary. Change aperture to get a better picture. 
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SDS-PAGE gel with Silver staining 
Sensitivity= .25 ng/band; 50 ng/well 
 
For purified sample- want 10 ug, for other samples 50-100 ug, adjust volume w/PBS 
Laemmli Sample buffer-2x sample buffer 475 ul + 25 ul 2- -mercaptoethanol) 
 
For 30 ul volume for 18 well gel- 15 ul of sample+ 15 ul 2x sample buffer w/2-me 
For 40 ul volume for 12 well gel- 20 ul of sample+ 20 ul 2x sample buffer w/2-me 
 
1. Mix well 
2. Heat to 95
o
C for 5 minutes 
3. Place on ice to cool 
4. Centrifuge several seconds 
5. Place at -80
 o
C for storage if not using immediately  
 
Purchase a pre-poured gel  
Biorad Criterion 4-20% Tris-Hcl gel with 14 or 18 wells 
(Biorad Labs, 2000 Alfred Nobel Dr. Hercules, CA  94547) 
 
Loading the gel 
1. Remove the white tab from the bottom of the gel.   
2. Carefully remove the comb. 
3. Use a syringe with a needle attached to flush the wells with running buffer just 
before loading to get rid of any unpolymerized polyacrylamide that may seep in. 
4. Insert the gel into the apparatus with the numbers facing outward. 
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5. Pour Tris-glycine electrophoresis buffer into the upper and lower chambers. Fill to 
within several mm of top and to the second line in the bottom chamber. Make 500 
ml of running buffer by adding 100 ml of 5X stock to 400 ml Ultrapur H20. 
6. When loading the gel, load something (1X loading buffer in blank lanes) in each 
lane and the dye will migrate more evenly. (Use SDS Standard, Broad Range, 
catalog # 161-0317 as size marker). Molecular weight markers 
7. Start large thin gels at a constant current of 15 mA/gel for 10 minutes then increase 
to 20 mA/gel for the remaining time. (Check in 1½ hrs). 
 
Staining the gel 
A- Silver Staining the gel (Pierce Silver Stain Kit 24612) - use constant gentle 
shaking 
1. Turn off machine and remove the lid (Use lid to break open the gel chamber) 
2. Pour off buffer from top chamber and cut off the wells 
3. Pull gel off from the bottom by lifting center with forceps and running fingers to 
edges (Bottom is tougher than the top) 
4. Place gel in plastic lid and wash for 5 min in ultrapur H20. Twice 
5. Fix gel for 15 min in 30% ethanol : 10% acetic acid soln. twice 
6. Wash gel for 5 min in 10% ethanol twice 
7. Wash for 5 min in ultrapur H20 twice 
8. 20) 
9. Wash for 1 min in ultrapur H20 twice  
10.  
11. Wash for 20 sec in ultrapur H20 twice 
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12. Develop gel for 2-
Developer) 
13. Stop with 5% acetic acid for 10 min. 
 
B- GelCode Blue Stain Reagent (Supplemental Figure 3.1) 
Directions: 
1- Wash gel three times with deionized water (15 minutes); 
2- Add GelCode Blue Stain Reagent (1 hour); 
3- For increase clarity, use the optional water wash enhancement step (1 hour). 
 
 
Supplemental Figure 3.1 Gel stained using GelCode blue stain. The marker is on the 
left of the gel and the size of each band is indicated (from 200 KDa to 6.5). The 
recombinant VapA protein (arrow) is identified between the 14.4 and the 21.5 marker. 
The size of the VapA is slightly larger as a small piece of the GST tag remains attached 
after protein purification (natural size of VapA is 14-17KDa)  
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Recipes 
 
Running buffer  
Make 500 ml by adding 100 ml of 5X stock to 400 ml Ultrapur H20 
 
Silver Stain  
30 ml ethanol + 10 mil glacial acetic acid + 60 ml H20* 
10 ml ethanol + 90 H20* 
Sensitizer 50 ul in 25 ml H20 
Enhancer 500 ul in 25 ml stain 
Developer Work solution 500 ul enhancer in 25 ml developer 
5 ml glacial acetic acid + 95 ml H20* 
* = can be made in advance 
 
5X TBE for 1L 
54 gm Tris Base 
27.5 gm Boric Acid 
40 ml 0.25 M EDTA pH 8.0 
 
Use @ .5X for agarose gels 
1x for polyacrylamide gels 
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Bradford Assay Protocol 
Make standard using BSA at 1 mg/ml stock solution.  Make 1:10 dilutions and perform 
in singlets. 
 
Sample= 200 ul Bradford solution + 800 ul ultrapur H20 + 10 ul sample (protein) 
If sample turns dark or bright blue when you add the sample to the Bradford solution, 
the concentration is too high and you need to perform a 1:10 dilution of the sample. 
 
Standard must go through 0 or it is not able to measure low concentrations 
Thaw protein samples on ice. 
 
Read on spectrophotometer using “Bradford” settings. First tube is always the blank 
 
The protein binds the Coumassie and forms a precipitate. The precipitate settles out and 
you get an erroneous reading. Therefore, you must work quickly. 
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Chemicals  
at -20oC 
100ug/ml = 2 ml Amp/500 ml broth, .5 ml Amp/125 ml broth, 20 ul Amp/5 ml broth 
50 ug/ml= 1 ml Amp/500 ml broth, .25 ml Amp/125 ml broth, 10 ul Amp/5 ml broth 
 
IPTG (isopropylthio-beta-D-galactoside)- BP1620-10 Fisher Scientific- keep in 
desiccator in -20oC freezer  
 40 mg/ml 1250 ul per 500 ml bacteria 
 1 g =25 ml=20 tubes of 1250 ul 
 10 g=250 ml=200 tubes of 1250 ul; 50 tubes of 5 ml 
 Allow to warm to room temperature, soluble in H20 
 In Chemical Fume Hood- Use ultrapur H20 25 ml + 1 g powder.  Vortex to mix.  
Store aliquots in -20oC 
 
PMSF (phenylmethylsulfonyl fluoride- protease inhibitor)- .44 g in 25 ml ethanol = 100 
mM stock- In Chemical Fume Hood- remake fresh every 6 weeks- loses potency. Store 
in fridge. 
 
Triton-X-100  20% stock solution to a [final] of 1% when added to the solution. (1ml 
per 20 ml; 1.25 ml per 25 ml) Store in fridge. 
 
Thrombin (GE Healthcare product # 27-0846-01)- add 500 ul ultrapur H20 to bottle and 
aliquot in 50 or 100 ul volumes; store at -80oC 
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1M solutions = Dry= M x MW x V= g 
Hydrated= M x V x # H20 x 18.015 = ml H20 contributed by hydrated compound. 
 
1) Tris Base MW=121.14  
 For 100 ml 
 = 121.4 x 1M/1 x 100/1000 ml 
 = 12.114 g Tris Base →dissolve in ~60 ml H20 
 pH to 8.5 w/concentrated HCl to make Tris HCl 
 Adjust final volume to 100 ml with H20 (1) 
 
2) 1 M NaCl MW= 58.44 
 For 200 ml 
 =58.44 x 1M/1 x 100/1000 ml x 2 
 =5.844 g x 2 dissolved to a final volume of 200 ml H20 
 =11.688 in 200 ml H20 (2) 
 
Add 10 ml 1M TrisHCl + 50 ml 1M NaCl, bring to 100 ml w/ H20    (3) 
 
.1 M Na Acetate (Trihydrate) [CH3COONa∙3H20 MW 136.08] + .5M NaCl pH 4.5 
100 mM stock NaAcetate=1.36 gm in 100 ml H20 
 
1.36gm NaAcetate + 50 ml 1M NaCl, adjust pH w/glacial acetic acid to 4.5 
Bring to 100 ml w/H20 for 100 mM stock                                                         (4) 
 
 
  
 
109 
 
Glutathione elution buffer (200 ml)  
=307.3 x 10mM/1000 x 200ml/1000 
=0.615 g glutathione = 10 mM 
50 mM Tris=50/1000 x 200/1 =10 ml 1M Tris pH 8.5 
 
Add 100 ml H20 and dissolve .615 gm glutathione, add 10 ml 1 M Tris (pH 8.5) 
Adjust pH to 8.0 with HCl; adjust volume to 200 ml with H20                                 (5) 
 
Molecular weights 
KCl – 74.56 
KH2HPO4– 136.09 
Na Acetate – 136.08 
Na2HPO4– 141.96 
NaCl – 58.44 
MgCl – 95.21 
Reduced Glutathione - 307.3 
Tris Base -121.14 
 
Protocol 3.2 – VapA-specific IgG and IgG subclasses ELISA 
Materials 
Coating: Coat @ 0.5 ug/well for VapA over night @ 4ºC. Mix vapA with coating 
buffer) 
Blocking Buffer: Prepare 1% PVA block by mixing 1g PVA and 100mL ddH2O; heat 
and stir until dissolved (about 45 min) 
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Just before use dilute 1% PVA with PBS (1:1) 
Samples: Dilute samples at 1:100 with ELISA Wash Buffer 
Secondary antibody: Add 1uL goat-anti-horse IgG in 10mL Elisa wash (Peroxidase – 
conjugated AffiniPure Goat Anti-Horse IgG; Jackson Immuno Research, West Grove, 
PA) 
 
Procedure 
1- Add 100uL vapA coating solution per well. Refrigerate plate over-night. 
2- Wash plate 3 times with Washing Buffer, 300 ul per well. 
3- Add 200uL Blocking Buffer per well. Incubate 1 hr at RT on bench top. 
Note: Dilute Blocking Buffer before usage 1% PVA with PBS (1:1) 
4- Wash plate 3 times. 
5- Add 100uL diluted serum samples (duplicate). Incubate 1 hr at 37ºC. 
6- Wash 3 times 
For total IgG go to step 7, for specific R. equi istotype Ig test go to setp 8 
7- Add 100 ul secondary antibody (1:10000 dilution in washing buffer. Rabbit anti-
Horse IgG-Peroxidase, Sigma Aldrich-A9292). Incubate for 1 hr at 1 hr at 37ºC.  
8- Add 100 ul of secondary of mouse anti-horse IgGa, IgGb and IgGT, incubate 1 
hr at 37ºC. 
IgGa dilute at 1:100 in Washing Buffer for old supernatant. New hybridomas 1:2 
IgGb dilute at 1:10 in Washing Buffer (both old and new) 
IgGT dilute at 1:10 in Washing Buffer. New hybridomas 1:5 
9- Wash 3 times 
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10- 3rd Ab, HRP conjugated Goat anti-mouse Ig (1:2000 dilution in washing buffer, 
Goat anti-mouse IgG, Jackson ImmunoResearch, 108-035-003), add 100ul/well, 
incubate 1 hr at 37ºC. 
11- Wash 3 times 
12- Add 100uL SureBlue, incubate for 5 min keep out of light. 
13- Add 100uL Stopping solution. 
14- Read immediately at A450 nm and A630.   
Standard Curves 
Total IgG and IgGa: Use Mg Biologics R equi plasma. Start curve on 1:90 using a 1:3 
dilution factor. Seven points from there (to 1:65610) 
IgGb: Use Mg Biologics R equi plasma. Start curve on 1:270 using a 1:3 dilution 
factor. Seven points from there (to 196830) 
IgG(T): Use Plasvaac R equi plasma. Start curve on 1:16 using a 1:2 dilution factor. 
Seven points from there (to 1:1024) 
Note: Need a positive and negative controls, Blank, no VAP, no serum, no 2
nd
Ab, no 
3
rd
 Ab on a plate every time ELISA is run 
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